,PMCID,sentence_id,CONSORT_Item,labels,section,text
0,PMC3420230,S101,['6b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0]",Outcomes,"once the decision not to fund the main trial was known, a full statistical analysis plan was prepared with prespecified primary and secondary outcome measures; this was uploaded onto the trials website, with the date of amendment logged."
1,PMC3420230,S102,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Outcomes,no data were unblinded before this time.
2,PMC3420230,S103,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"for the ursodeoxycholic acid comparison, the primary outcome was itch in the mother, measured as the arithmetic mean of all post-randomisation measures of worst itch in the previous 24 hours assessed on a visual analogue scale."
3,PMC3420230,S104,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Outcomes,"to avoid over-interpretation of our results, we carried out two online surveys (www.surveymonkey.com) before unblinding of the trial to determine what reduction in score on the visual analogue scale would be a clinically meaningful difference among clinicians involved in treating women with intrahepatic cholestasis of pregnancy and among women who had previously experienced the condition (full questions given in supplementary appendix 1)."
4,PMC3420230,S105,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Outcomes,women and clinicians were informed that the mean baseline itch score on the visual analogue scale was 60 mm (by analysis of blinded data) and were offered a choice of answers.
5,PMC3420230,S106,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"for the timing of delivery comparison, the primary outcome was caesarean section."
6,PMC3420230,S107,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Outcomes,"it is widely believed that induction in general increases the rate of caesarean sections, although recent trials of timing of delivery at term have shown no significant effect.12 13"
7,PMC3420230,S108,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,secondary outcome measures for the ursodeoxycholic acid comparison were prespecified as maternal outcomes and perinatal outcomes.
8,PMC3420230,S109,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"maternal outcomes were average itch in past 24 hours (visual analogue scale); levels of total bile acids, alanine transaminase, and aspartate transaminase; mode of onset of labour; mode of delivery; indication for delivery; and blood loss at delivery."
9,PMC3420230,S110,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"perinatal outcomes were gestation at delivery, baby outcome, birth weight, presence of meconium stained amniotic fluid, arterial cord ph, venous cord ph, apgar score at five minutes, congenital anomalies, admission to a neonatal unit (including duration), need for ventilation (including duration), convulsions, and jaundice."
10,PMC3420230,S111,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"for the timing of delivery comparison, we chose the same secondary maternal and perinatal outcomes."
11,PMC3420230,S112,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Outcomes,"the outcome measures previously specified at the start of this initial phase of the trial were designed to measure the feasibility of the second phase—namely, recruitment to the two interventions (total recruitment rate per 1000 deliveries per annum and total recruitment rate per eligible women), recruitment rates related to disease severity, acceptability of randomisation among potential participants offered trial entry, adherence with each treatment arm, and completeness of outcome data."
12,PMC3420230,S114,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Parallel audit,all centres undertook an audit in parallel with the trial from the start of recruitment until 1 april 2010 (when the initial target of 90 women had been recruited).
13,PMC3420230,S115,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Parallel audit,"they identified all pregnant women with raised bile acid levels (in collaboration with each hospital’s chemical pathology laboratory) and undertook postnatal case note review to ascertain whether a diagnosis of intrahepatic cholestasis of pregnancy had been confirmed, what treatment had been given, and whether the participation in the trial had been offered."
14,PMC3420230,S116,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Parallel audit,the number of deliveries per centre per month during the audit period was obtained.
15,PMC3420230,S118,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,"for the planned factorial trial, we estimated that a provisional sample size would be 1498 women (749 per group)."
16,PMC3420230,S119,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,"this would give 80% power, α 0.05, to show a reduction in the primary composite endpoint (fetal death or severe morbidity) from 6% to 3%."
17,PMC3420230,S120,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,"however, detailed power calculations were not possible without an accurate estimate of the event rate and the clinical spectrum of likely recruits to such a trial."
18,PMC3420230,S121,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,the target sample size of the initial phase was determined to be about 90 participants to allow reasonably precise estimates of the variables for the main trial.
19,PMC3420230,S122,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,"after the decision to analyse the initial phase alone and before unblinding, we undertook a sample size calculation based on our new primary outcome measure of maternal itch score with the clinically meaningful difference as determined."
20,PMC3420230,S123,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,this confirmed that the study as carried out had over 99.9% power to detect a difference of 30 mm (with a standard deviation of 26 mm across both arms and a correlation between baseline and follow-up measurements).
21,PMC3420230,S125,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"trial analysis followed the intention to treat principle, with women and infants analysed according to the original randomised allocation, irrespective of adherence and crossovers."
22,PMC3420230,S126,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"for repeated measurements over time (severity of itch and biochemistry), we used the average (arithmetic or geometric mean) during the intervention period.19"
23,PMC3420230,S127,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"in all analyses, regression methods were used and adjustment made for stratification variables (gestation at recruitment for ursodeoxycholic acid trial only, and study centre for both trials) and for potential confounders (baseline bile acid levels, and others where the imbalance was substantial)."
24,PMC3420230,S128,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,for the analysis of perinatal outcomes we treated all infants (singletons or twins) equally.
25,PMC3420230,S129,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"to allow for multiple pregnancy, we adjusted standard errors for clustering by mother using the huber-white sandwich estimator, and multiplicity included as a covariate.20"
26,PMC3420230,S130,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,mode of delivery was expressed as a perinatal outcome owing to the inclusion of twin pregnancies in which the mode of delivery may be different for one twin.
27,PMC3420230,S131,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,for continuous outcomes (such as visual analogue scale measurement and biochemical results) covariates included the baseline measurement.21
28,PMC3420230,S132,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,because of the spread and distribution of values we based the analysis of biochemical markers on logged values.
29,PMC3420230,S133,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,the treatment effect was presented as a concentration ratio (the ratio between treatment groups of the geometric mean concentration post-randomisation).
30,PMC3420230,S134,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,we estimated risk ratios and risk differences for yes or no outcomes; we used binary regression with a log-link (for risk ratios) and a linear link (for risk differences).
31,PMC3420230,S135,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,time to delivery was treated as partially censored data and analysed using cox’s proportional hazards.
32,PMC3420230,S136,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"for the ursodeoxycholic acid comparison, censoring was at delivery (if after 37 weeks) for pregnancies randomised to the early term delivery arm of the other trial and undergoing induction of labour or caesarean section owing to trial allocation (rather than maternal or fetal compromise or the request of the mother or obstetrician); and otherwise at 40 weeks."
33,PMC3420230,S137,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"for the timing of delivery comparison, censoring was at 40 weeks in all cases."
34,PMC3420230,S138,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"for subgroup analyses, the principal subgroup was level of bile acids at baseline (continuous and in three categories: normal with raised alanine transaminase levels (bile acids 14 µmol/l, alanine transaminase >100 u/l), mild (bile acids 15-40 µmol/l), and severe (bile acids >40 µmol/l)."
35,PMC3420230,S139,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"we used interaction tests to determine whether apparent differences in treatment effect between groups could be interpreted as real (not due to chance only), and hence to indentify subgroups that might or might not benefit from randomised treatment."
36,PMC3420230,S140,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"analyses were done in the statistical package stata version 11.1 or later (statacorp, college station, tx)."
37,PMC3420230,S142,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Ethical approval,the protocol22 was published at the start of the trial.
38,PMC3420230,S143,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Ethical approval,the updated statistical analysis plan was uploaded onto the trials website before unblinding of the data and incorporated into the revised protocol.
39,PMC3420230,S144,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Ethical approval,the trial is reported in accordance with the consolidated standards of reporting trials guidelines.
40,PMC3420230,S54,"['3a', '4b']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,we undertook a semifactorial randomised controlled trial of two interventions in women with intrahepatic cholestasis of pregnancy at nine maternity units in the united kingdom.
41,PMC3420230,S55,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,the trial began in two centres in october 2008 and the remainder joined in over the following year as regulatory approvals were obtained.
42,PMC3420230,S56,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,"women were eligible if they had confirmed intrahepatic cholestasis of pregnancy (itching in pregnancy with other causes excluded, in association with a serum bile acid level greater than the upper limit of normal for that unit’s laboratory) or if they had pruritus with raised alanine transaminase levels (>100 iu/l) and were between 24+0 and 40+6 weeks pregnant for the ursodeoxycholic acid comparison or between 34+1 and 37+6 weeks with a singleton pregnancy for the timing of delivery comparison."
43,PMC3420230,S57,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,"we excluded women who were aged less than 18 years; had laboratory confirmed hepatitis a or hepatitis b, pre-eclampsia, primary hepatic disorders, known α-1 antitrypsin deficiency, or current drugs causing deranged liver enzymes; were known to have a lethal fetal anomaly; had an allergy to any component of the ursodeoxycholic acid or placebo capsules; or were unable to give informed consent."
44,PMC3420230,S58,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,"women with concurrent hepatitis c or cholelithiasis, or both, were eligible."
45,PMC3420230,S59,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,women with a multiple pregnancy were eligible only for the ursodeoxycholic acid comparison as most participating clinicians indicated that such women should normally be delivered at 38 weeks’ gestation.
46,PMC3420230,S61,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,"clinicians and midwives approached women attending the antenatal clinic, the antenatal day assessment units, or the antenatal ward about participating in the study."
47,PMC3420230,S62,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,"a member of the research team confirmed eligibility, gave the women detailed verbal information and an information sheet and invited them to take part."
48,PMC3420230,S63,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,the usual hospital interpreter and translator services were available.
49,PMC3420230,S64,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,"the participants provided written, dated informed consent, and the women’s consultant obstetricians and general practitioners were informed of their participation."
50,PMC3420230,S65,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,"a member of the research team confirmed participant eligibility and entered an agreed minimum amount of pre-randomisation registration data on a secure internet based data form about the participant before randomisation, including the results of routine biochemical blood tests."
51,PMC3420230,S66,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,randomisation occurred through the nottingham clinical trials unit using a web based database and randomisation system.
52,PMC3420230,S67,"['8a', '8b']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0]",Recruitment and randomisation,"the random allocation sequence for each comparison was generated by using a specific function (-ralloc-) in stata (statacorp, college station, tx) software within the clinical unit using randomly varying block sizes of two, four, and six."
53,PMC3420230,S68,['9'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1]",Recruitment and randomisation,the random allocation sequence was not revealed until all data outcomes had been collected and the statistical analysis plan registered.
54,PMC3420230,S69,['8b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Recruitment and randomisation,randomisation was stratified by the gestation at recruitment for the ursodeoxycholic acid comparison and by trial centre for both comparisons.
55,PMC3420230,S70,['8b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Recruitment and randomisation,randomisation for both comparisons within the trial was in a 1 to 1 allocation ratio.
56,PMC3420230,S71,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,women who were eligible for both were permitted to participate in either or both factorial comparisons.
57,PMC3420230,S72,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,"those who participated in the drug comparison before 34 weeks’ gestation were not allowed to join the timed delivery comparison until 34 weeks, so for that group, randomisation to the two treatment comparisons occurred at different times."
58,PMC3420230,S73,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,allocation occurred centrally at the clinical unit using a web based database.
59,PMC3420230,S74,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,"on randomisation, the clinical unit’s internet trial system issued a unique participant identification number and the participant was randomised to one or both trials according to eligibility."
60,PMC3420230,S75,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,sequentially numbered containers were sent to the clinical trial’s pharmacist at each centre at the start of the trial and all packs kept in the pharmacy until distribution to the participant.
61,PMC3420230,S76,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,"after randomisation to the ursodeoxycholic acid or placebo comparison, an online prescription form was generated for printing."
62,PMC3420230,S77,['9'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1]",Recruitment and randomisation,the participant collected the trial drug or placebo from the hospital pharmacy once the local trial’s pharmacist had selected the pack with the appropriate number.
63,PMC3420230,S78,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,"the investigator, pharmacist, and trial participant were blind to group allocation."
64,PMC3420230,S79,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,"for the timing of delivery comparison, the investigator and participant could not be blinded to the treatment group and appropriate arrangements were made for induction or elective delivery or expectant management as allocated."
65,PMC3420230,S80,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,"obstetricians were permitted to induce participants in the expectant management group from 40+0 weeks’ gestation, or as clinical needs dictated."
66,PMC3420230,S81,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,"other than the trial randomisation, women were managed in accordance with each unit’s guideline for intrahepatic cholestasis of pregnancy, with frequency of blood testing and fetal monitoring determined by the local clinicians."
67,PMC3420230,S82,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,all centres were aware of the royal college of obstetricians and gynaecologists’ guidelines for management of obstetric cholestasis.8
68,PMC3420230,S84,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Follow-up,"after randomisation, a member of the research team saw participants weekly at the time of their routine clinical visit."
69,PMC3420230,S85,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Follow-up,"the participant was asked about adherence to treatment, use of other drugs, and adverse events, and completed the visual analogue scale for itching."
70,PMC3420230,S86,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Follow-up,results of routinely collected biochemical tests were recorded.
71,PMC3420230,S87,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Follow-up,participants were seen six weeks after delivery.
72,PMC3420230,S88,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Follow-up,"all maternal and perinatal outcomes were collected by review of postnatal case notes, with adjudication where necessary by the trial management group."
73,PMC3420230,S89,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Follow-up,participants were able to withdraw from the trial at either their own request or the discretion of the treating clinician.
74,PMC3420230,S90,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Follow-up,"if a participant’s clinical condition deteriorated (for example, worsening of itch, increasing bile acid levels), the clinician could decide to stop the trial drug and give ursodeoxycholic acid, or deliver the woman if indicated, without breaking the treatment code."
75,PMC3420230,S92,"['11b', '5']","[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Interventions,"women in the first comparison were randomised to ursodeoxycholic acid (250 mg dose; ursofalk, dr falk pharma, buckinghamshire), or to placebo capsules (dr falk pharma) identical in appearance and taste to the study drug (white, opaque, hard gelatin capsule)."
76,PMC3420230,S93,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Interventions,the placebo contained lactose monohydrate and magnesium stearate.
77,PMC3420230,S94,['11b'],"[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Interventions,"all capsules were packaged and labelled to provide blinded treatment packs in the production unit of the pharmacy department, nottingham university hospitals nhs trust."
78,PMC3420230,S95,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Interventions,supplies were packed in an approved container and tagged with a single panel label.
79,PMC3420230,S96,['9'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1]",Interventions,"the participant’s name, randomisation number, and date of dispensing were added to the label as part of the dispensing process."
80,PMC3420230,S97,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Interventions,all women received two capsules twice a day and if there was no clinical improvement (itching) or biochemical improvement (serum bile acids or alanine transaminase levels) the dose was increased in increments of two capsules per day every 3-14 days up to a maximum of 2 g/day.
81,PMC3420230,S98,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Interventions,"women in the second comparison were randomised to early term delivery (induction or delivery started between 37+0 and 37+6) or to expectant management (where spontaneous labour was awaited or caesarean delivery undertaken according to normal obstetric guidelines, usually after 39 weeks’ gestation)."
82,PMC3420230,S99,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Interventions,"by consensus, obstetricians could arrange delivery in the latter group from 40+0 weeks’ gestation."
83,PMC3944682,S100,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Analysis,"the likelihood ratio test is particularly useful for assessing the effect of variables with multiple levels (for example, the delayed prescribing factor, with five levels), and provides an overall test of whether the variable makes a significant difference to the statistical model."
84,PMC3944682,S101,"['12a', '7b']","[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0]",Analysis,"analysis was intention to treat (that is, practitioners or patients were analysed in their intended randomisation groups, whether or not they complied), but we did not impute missing values, there was no interim analysis, and no clinical subgroups for antibiotic prescribing strategies were specified in advance."
85,PMC3944682,S33,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of study design and trial groups,"this study was a pragmatic open factorial trial of delayed antibiotic strategies, controlling for symptomatic advice regarding analgesia and steam, with a parallel observational component for patients judged to need immediate antibiotics."
86,PMC3944682,S34,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of study design and trial groups,"health professionals, who were mainly doctors but also some practice nurses, decided in negotiation with patients whether immediate antibiotics were needed."
87,PMC3944682,S35,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Summary of study design and trial groups,"if antibiotics were not needed, patients were randomised to one of four delayed prescribing groups: recontact for a prescription, post-dated prescription, collection of the prescription, or patient led (that is, the patient was given the prescription)."
88,PMC3944682,S36,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of study design and trial groups,the figure and web appendix 1 provides more detail on these groups.
89,PMC3944682,S37,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of study design and trial groups,consort flow diagram.
90,PMC3944682,S38,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of study design and trial groups,"of 889 patients considered, 556 were judged not to require immediate antibiotics and were randomised."
91,PMC3944682,S39,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of study design and trial groups,*numbers based on general practitioner reports
92,PMC3944682,S40,['8b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Summary of study design and trial groups,each group was randomised further into 12 subgroups according to three factors.
93,PMC3944682,S41,['8b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Summary of study design and trial groups,"these factors were antipyretic regimens (ibuprofen, paracetamol, or both combined), regular antipyretic versus “as required” dosing, and steam inhalation advice versus no advice to inhale with steam."
94,PMC3944682,S42,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of study design and trial groups,the web figure uses an example group (no prescription) to illustrate this randomisation process.
95,PMC3944682,S43,['3b'],"[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of study design and trial groups,"during the trial (from january 2011), a strategy of no antibiotic prescription was added as a randomised comparison, bringing the total number of randomised groups to five (fig 1)."
96,PMC3944682,S46,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,"we chose a factorial design for the analgesic and steam components to deal with the management of symptoms, and the antibiotic component particularly to deal with antibiotic use and beliefs in antibiotics."
97,PMC3944682,S47,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,"the factorial design is not only efficient in assessing multiple interventions, but also provides better control of symptomatic advice (regarding analgesia or steam) that could plausibly affect symptom control in the antibiotic groups."
98,PMC3944682,S48,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,a non-randomised immediate prescription group was chosen to allow all patients to enter the study and provide two important opportunities.
99,PMC3944682,S49,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,"firstly, to observe how often immediate antibiotics are thought necessary by clinicians, and secondly, to be able to compare patient outcomes in those prescribed and not prescribed antibiotics."
100,PMC3944682,S50,['3b'],"[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,"during the study, it became clear from systematic reviews that delayed prescribing might result in higher antibiotic use than no initial prescription.8"
101,PMC3944682,S51,['3b'],"[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,"we therefore added a no prescription group to facilitate interpretation of the effect of delayed prescription compared with the alternatives strategies, particularly because both the delayed and no prescription groups in the current study had higher antibiotic use than in previous studies."
102,PMC3944682,S53,"['8a', '10']","[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0]",Summary of rationales,a statistician independent of the study team coordinated the randomisation using computer generated random numbers.
103,PMC3944682,S54,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,"if the doctor thought that immediate antibiotics were definitely required, they prescribed antibiotics, otherwise patients were randomised to one of four methods of delayed antibiotic prescribing."
104,PMC3944682,S55,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,we assessed evidence of subversion of randomisation by monitoring the order of use of envelopes (there was no evidence of selective envelope use) and the baseline table (which showed that the groups were well balanced).
105,PMC3944682,S56,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,a key concern in complex pragmatic factorial trials is keeping the logistics simple and avoiding errors at the point of intervention delivery.
106,PMC3944682,S57,['9'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1]",Summary of rationales,"we made it very simple to execute randomisation and delivery because the health professional took the next pack off the shelf that contained pre-randomised advice sheets (that is, there was no requirement—and hence no error—in finding and using the correct advice sheets)."
107,PMC3944682,S58,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,"with careful attention to practitioner equipoise, this method of randomisation to different advice strategies has proved successful in previous trials.11 13 14"
108,PMC3944682,S59,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,there was no evidence of subversion in the current study—either for selective envelope use or bias in patient characteristics.
109,PMC3944682,S61,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,the study included patients aged 3 years and over presenting to a health professional (a general practitioner or nurse).
110,PMC3944682,S62,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,"patients had to present in a general practice setting with a respiratory tract infection diagnosed by the health professional (acute cold, influenza, sore throat, otitis media, sinusitis, croup, or lower respiratory tract infection)."
111,PMC3944682,S63,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,patient or parental written consent was given.
112,PMC3944682,S64,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,"patients were excluded if they were asthmatic (unless ibuprofen or aspirin previously provided no problems), had active or previous peptic ulceration, were hypersensitive to analgesics, and were unable to complete outcome measures (for example, they were visually impaired, had psychosis, or were severely depressed)."
113,PMC3944682,S65,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,"exclusion also applied to patients who required hospital admission (for example, for meningitis, severe pneumonia, epiglottitis, or kawasaki disease), had a known immune deficiency, or were pregnant or breastfeeding."
114,PMC3944682,S67,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,the primary outcome was symptom severity measured at the end of each day during days 2-4 of a two week symptom diary (days 2-4 are when symptoms of all respiratory infections are at their worst11 14).
115,PMC3944682,S68,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Outcomes,we chose symptom severity as a key outcome because the most recent systematic review documented worse symptom control with delayed prescription.8
116,PMC3944682,S69,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,the diary was completed by patients (or children) until symptoms returned to normal.
117,PMC3944682,S70,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"it used previously validated formats11 15 for rating symptoms (0=no problem, 6=as bad as it could be)."
118,PMC3944682,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"symptoms included feeling generally unwell, sleep disturbance, fever, interference with normal activities, sore throat, cough, short of breath, facial or sinus pain, earache, and runny or blocked nose."
119,PMC3944682,S72,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,symptom resolution was a secondary outcome because duration differs according to the particular respiratory infection.7
120,PMC3944682,S73,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,patients were telephoned (on days 2-3) to check for any problems with diary completion.
121,PMC3944682,S74,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Outcomes,"if no diary was received after two weeks, one mailed reminder was sent and then a phone call made as necessary to document key outcomes using a brief questionnaire—which we have shown to be reliable.13"
122,PMC3944682,S75,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Outcomes,secondary outcomes were:
123,PMC3944682,S76,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"any antibiotic use in the 14 days after recruitment, as documented in the diary or the brief questionnaire"
124,PMC3944682,S77,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"side effects (rash, diarrhoea, vomiting, or abdominal pain) documented in the diary"
125,PMC3944682,S78,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,mean temperature readings in the morning and evening using tempadot thermometers (orally where possible)
126,PMC3944682,S79,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,duration of symptoms: rated moderately bad or worse
127,PMC3944682,S80,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"return with new or worsening symptoms or complications of intervention—that is, a patient returning with a symptom or diagnosis of respiratory tract infection recorded using a structured proforma by a member of the research team."
128,PMC3944682,S81,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"complications were defined as a new consultation documented in the notes within one month with otitis media, sinusitis, pneumonia, quinsy, cervical adenitis, meningitis, or septicaemia"
129,PMC3944682,S82,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"belief in the effectiveness of antibiotics and satisfaction, measured in the main diary using previously developed questions13"
130,PMC3944682,S83,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,general practitioners were asked to complete non-recruitment logs and a questionnaire at the end of the study documenting the common reasons for non-recruitment of eligible patients and for eligible patients who declined.
131,PMC3944682,S85,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size calculation ,we calculated the sample size based on an α value of 0.05 and β value of 0.2 using the nquery program for multiple group sample sizes.
132,PMC3944682,S86,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size calculation ,"there were two elements to the calculation, firstly for symptom control (the primary outcome), and secondly for antibiotic use."
133,PMC3944682,S87,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size calculation ,we assumed a standard deviation of 1.1 for our primary outcome.11 13 15
134,PMC3944682,S88,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size calculation ,"assuming that one analgesic group had symptom control that was 0.5 standard deviations better than one of the other groups (that is, a moderate effect size), 228 patients were needed to allow for 12 groups and 80% follow-up, or 504 patients for 0.33 standard deviations."
135,PMC3944682,S89,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size calculation ,"this effect size was equivalent to one in three people rating symptoms as mild rather than moderate, agreed as a modest effect size by the trial steering committee of a medical research council funded trial of prescribing strategies for acute cough11)."
136,PMC3944682,S90,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Sample size calculation ,"for the antibiotic outcome of the antibiotic strategies (a key outcome for this component of the study), we compared the difference in antibiotic use between the delayed strategies and no antibiotic prescription."
137,PMC3944682,S91,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size calculation ,"seventy two patients per group or 450 in total were needed in the groups with no prescription or delayed prescription, allowing for 20% loss to follow-up."
138,PMC3944682,S92,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size calculation ,"these numbers also assumed 15% use of antibiotics in the no antibiotic group, and 20-35% use in the delayed prescription groups (20%, 25%, 35%, and 35% for recontact, post-date, collection, and patient led, respectively)."
139,PMC3944682,S93,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size calculation ,we estimated that 72 patients per group would provide 80% power to detect a difference of 0.5 standard deviations in symptom control between delayed prescription groups and the no prescription group.
140,PMC3944682,S95,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Analysis,we performed an analysis of the randomised groups and a secondary analysis that included the non-randomised immediate group.
141,PMC3944682,S96,"['12a', '12b']","[0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Analysis,"we used analysis of covariance for a factorial study for the main continuous outcomes, controlling for stratification, analgesic and steam strategies, and confounders if appropriate."
142,PMC3944682,S97,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Analysis,"logistic regression was used for antibiotic use and return to the surgery, and cox regression was used for the duration of symptoms."
143,PMC3944682,S98,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Analysis,odds ratios were converted to risk ratios using standard formulas.16
144,PMC3944682,S99,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Analysis,"the effect of antibiotic strategies, and interactions, were assessed using the likelihood ratio χ2 test."
145,PMC4797126,S100,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,sample size determination
146,PMC4797126,S101,"['3a', '7a']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical methods,we planned to randomize 560 patients to one of three dose regimens of quilizumab or placebo in a 1:1:1:1 ratio (140 patients per group).
147,PMC4797126,S102,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical methods,"this sample size provided approximately 84 % power to detect a 50 % reduction in average exacerbation rates due to quilizumab, assuming 0.63 exacerbations per patient in the placebo group over a 36-week treatment period, and a significance level of α = 0.10."
148,PMC4797126,S103,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical methods,"this sample size also provided approximately 70 % power to detect a 50 % reduction in average exacerbation rates in the subgroup of periostin-high patients, assuming 0.69 exacerbations per patient in the placebo group over the 36-week period, a significance level of 0.15, and 50 % of patients in each treatment arm to be periostin high."
149,PMC4797126,S44,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,methods
150,PMC4797126,S45,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design,trial design
151,PMC4797126,S46,"['3a', '4b', '4a']","[0, 0, 0, 0, 0, 0, 1, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design,"the costa trial of quilizumab was a phase ii, randomized, double-blind, placebo-controlled study (including recruiting sites from 14 countries: argentina, belgium, bulgaria, canada, germany, hungary, mexico, new zealand, peru, poland, romania, russia, ukraine, and the united states) that enrolled 578 adults with uncontrolled allergic asthma."
152,PMC4797126,S47,"['3a', '8a', '5']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0]",Trial design,patients were randomly assigned (1:1:1:1) to one of three dosing regimens of quilizumab or placebo using an interactive web response system.
153,PMC4797126,S48,['8b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Trial design,"randomization was stratified based on serum periostin level (<50 ng/ml, ≥50 ng/ml), exacerbation history (number of exacerbations (1, >1) requiring use of systemic corticosteroids in the prior 18 months), ige level (≤75 iu/ml, 75–200 iu/ml, >200 iu/ml), and country."
154,PMC4797126,S49,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design,patients and study site personnel were blinded to treatment assignments until all follow-up data through week 84 were collected and verified.
155,PMC4797126,S50,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Trial design,"quilizumab (genentech, inc., south san francisco, ca) was delivered subcutaneously at nine monthly intervals at 300 mg per dose (300 mg m), or at three quarterly intervals and at week 4 at 150 or 450 mg per dose (150 or 450 mg q)."
156,PMC4797126,S51,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Trial design,the treatment period ended 36 weeks after randomization and was followed by a 48-week period to assess the sustained efficacy and safety of quilizumab (see additional file 1: figure s1).
157,PMC4797126,S52,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design,"ethics, consent, and permissions"
158,PMC4797126,S53,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design,"quorum review based in seattle, wa was the primary central irb used by sites in north america, however multiple other site-specific institutional review boards at other global sites approved the protocol and patients gave written, informed consent."
159,PMC4797126,S54,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design,"the trial was conducted in full conformance with the international conference on harmonisation e6 guidelines and the declaration of helsinki, or laws and regulations of the country where the research was conducted, whichever afforded greater protection to the individual."
160,PMC4797126,S55,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,participants
161,PMC4797126,S56,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,inclusion criteria
162,PMC4797126,S57,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,"adult asthma patients, aged 18–75 years, were required to have: bronchodilator reversibility of either ≥12 % β-agonist reversibility using 4 puffs of a short-acting β − agonist (saba) or a pc20 fev1 methacholine (provocative concentration of methacholine producing a 20 % fall in fev1 (forced expiratory volume in 1 s)) of 8 mg/ml or less, within the last 2 years; a pre-bronchodilator fev1 at screening of 40–80 % predicted; daily use of ics (≥400 μg/day total daily dose of fluticasone propionate or equivalent) and a second controller for a minimum of 3 consecutive months; inadequately-controlled asthma as documented by a 5-item asthma control questionnaire (acq-5) [21] score ≥1.50 at screening and randomization, despite compliance with asthma controller therapy; at least one positive aeroallergen-specific ige (≥0.35 ku(a)/l), or a total serum ige ≥75 iu/ml; and a history of at least one protocol-defined asthma exacerbation in the 18 months prior to screening."
163,PMC4797126,S58,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Participants,"asthma exacerbations were defined as new or increased asthma symptoms (wheezing, cough, chest tightness, shortness of breath, or nighttime awakening due to symptoms) that led to treatment with systemic corticosteroids for at least 3 days or to hospitalization."
164,PMC4797126,S59,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,exclusion criteria
165,PMC4797126,S60,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,"patients were excluded from the study if they had an asthma exacerbation requiring systemic steroids in the 30 days prior to screening, or between screening and randomization, a >20 % relative change in fev1 between screening and randomization, any pre-existing active lung disease other than asthma, any infections, elevated ige levels for reasons other than allergy, or were former or current smokers."
166,PMC4797126,S61,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Outcome measures,outcome measures
167,PMC4797126,S62,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcome measures,the primary efficacy outcome was the annualized rate of protocol-defined asthma exacerbations from baseline to week 36.
168,PMC4797126,S63,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcome measures,"secondary efficacy outcomes included assessments of lung function using the relative change in pre-bronchodilator fev1 from baseline to weeks 12 and 36 and the change in asthma symptoms from baseline to week 36, using total and daytime symptom severity scores derived from a daily patient diary."
169,PMC4797126,S64,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcome measures,the diary was also used to determine the proportion of patients who had no nighttime awakenings due to asthma symptoms and the proportion of patients with fewer than 2 days of saba use per week by week 36.
170,PMC4797126,S65,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcome measures,"exploratory outcome measures included the change in asthma control from baseline to week 36, as measured by the acq-5."
171,PMC4797126,S66,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcome measures,"to assess the change in allergy-related quality-of-life measures from baseline to week 36, the standardized asthma quality of life questionnaire (aqlq(s)) [22] and the standardized rhinoconjunctivitis quality of life questionnaire (rqlq(s)) [23] were administered at patient visits throughout the treatment and follow-up periods."
172,PMC4797126,S67,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcome measures,"we also evaluated the ability of biomarkers (serum periostin, blood eosinophils, exhaled no, and serum ige) to predict benefit from quilizumab."
173,PMC4797126,S68,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcome measures,safety outcomes were assessed throughout the 36-week treatment and 48-week follow-up periods.
174,PMC4797126,S69,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Assessments,assessments
175,PMC4797126,S70,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"the patient daily diary included two sections in addition to peak flow measurements: 1) a morning section capturing awakenings and rescue medication use at night, and symptoms on awakening; and 2) an evening section capturing daytime symptom severity, rescue medication use, preventive inhaler use, activity impairment during the day, and nasal symptoms."
176,PMC4797126,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"the modified total asthma symptom score (mtass) was generated from a subset of diary questions adapted from a previous questionnaire [24], scoring nighttime awakenings (0–3), symptoms on awakening (0–1), and daytime symptom severity (0–4), for a total score range of 0–8."
177,PMC4797126,S72,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"for the analyses of symptom scores, rescue medication use, and nighttime awakenings, daily scores were averaged over the previous 7 days prior to the time point of interest."
178,PMC4797126,S73,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,baseline values were derived from a minimum of 10 days of patient diary entries during the 14 days prior to the first treatment.
179,PMC4797126,S74,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Pharmacokinetics and immunogenicity,pharmacokinetics and immunogenicity
180,PMC4797126,S75,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Pharmacokinetics and immunogenicity,"serum levels of quilizumab for pharmacokinetic assessments were measured using a validated enzyme-linked immunosorbent assay (elisa; genentech, inc., south san francisco, ca)."
181,PMC4797126,S76,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Pharmacokinetics and immunogenicity,"the pharmacokinetic outcomes included: serum concentrations prior to dosing at weeks 0, 4, 12, 24, and 32; serum concentrations at week 5 and week 25; maximum observed serum concentrations (cmax,obs); time of maximum observed serum concentration (tmax, obs); and terminal elimination half-life (t1/2)."
182,PMC4797126,S77,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Pharmacokinetics and immunogenicity,"serum anti-therapeutic antibodies (atas) were assessed in samples at weeks 0, 4, 12, 24, 36, 48, 60, and 84 using a validated bridging elisa (genentech, inc., south san francisco, ca)."
183,PMC4797126,S78,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Biomarkers,biomarkers
184,PMC4797126,S79,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Biomarkers,samples for biomarker assessments were collected throughout the study.
185,PMC4797126,S80,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Biomarkers,"allergen-specific and total ige were measured in serum by immunocap® specific ige blood tests (viracor-ibt laboratories, lee’s summit, mo)."
186,PMC4797126,S81,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Biomarkers,"specific ige was measured for the following allergens: cat, house dust mite (hdm) dermatophagoides farinae, hdm dermatophagoides pteronyssinus, ragweed, aspergillus, timothy grass, bermuda grass, oak, birch, plantain, and orchard grass."
187,PMC4797126,S82,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Biomarkers,the maximum specific ige was defined as the specific ige with the highest titer of specific iges pre-dose in each patient.
188,PMC4797126,S83,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Biomarkers,"only observed values of ige levels were analyzed, with no imputation performed for missing ige data."
189,PMC4797126,S84,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Biomarkers,peripheral blood eosinophil counts were obtained from standard complete blood counts.
190,PMC4797126,S85,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Biomarkers,"serum periostin was measured by immunoassay using the roche elecsys platform (roche diagnostics ltd., rotkreuz, switzerland)."
191,PMC4797126,S86,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Biomarkers,"fractional exhaled nitric oxide (feno) was measured using a hand-held portable device, niox mino® (niox; morrisville, nc), according to american thoracic society/european respiratory society 2009 guidelines [25]."
192,PMC4797126,S87,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,statistical methods
193,PMC4797126,S88,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"all patients received at least one dose of study drug (intention-to-treat, itt population) and were included in all safety and efficacy analyses."
194,PMC4797126,S89,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,demographic and baseline characteristics were summarized using descriptive statistics.
195,PMC4797126,S90,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical methods,"the primary endpoint, the annualized exacerbation rate, was calculated by the total number of protocol-defined exacerbations observed in the group over the treatment period divided by total patient-weeks at risk (number of weeks from first study drug administration to the earliest of week 36 or study discontinuation) for the group and multiplied by 52."
196,PMC4797126,S91,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"for patients who discontinued the study prematurely, there was no imputation of additional exacerbations."
197,PMC4797126,S92,"['12a', '12b']","[0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"the rates of asthma exacerbations were compared between study groups using a poisson regression with overdispersion model, including terms for periostin status (<50, ≥50 ng/ml), number of prior exacerbations (1, >1), and ige level (<200, ≥200 iu/ml)."
198,PMC4797126,S93,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"for biomarker subgroup analyses, unadjusted asthma exacerbation rates were calculated."
199,PMC4797126,S94,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,corresponding two-sided p-values and 90 % confidence intervals (ci) were reported.
200,PMC4797126,S95,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,the relative change in pre-bronchodilator fev1 from baseline was calculated as the absolute change in fev1 (volume in liters) from baseline divided by the fev1 at baseline.
201,PMC4797126,S96,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"for secondary and exploratory end points, the means and standard deviations of all values for relative change were calculated according to study group at weeks 12 and 36."
202,PMC4797126,S97,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"the mean relative changes from baseline were compared between the study groups using the differences between the means for each group, with the associated two-sided 90 % cis."
203,PMC4797126,S98,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"missing values were imputed using the last-observation-carried-forward (locf) approach, as prespecified in the statistical analysis plan."
204,PMC4797126,S99,"['12a', '12b']","[0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"an analysis of covariance (ancova) model with factors for baseline level, periostin status (<50 ng/ml, ≥50 ng/ml), number of prior exacerbations (1, >1), and ige level (<200 iu/ml, ≥200 iu/ml) was fit to assess the treatment effect."
205,PMC4893154,S27,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population,vindicate was a randomized placebo-controlled double-blind trial of vitamin d supplementation in vitamin d−deficient chronic hf patients on optimal medical therapy.
206,PMC4893154,S28,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population,"patients were eligible if they had stable (>3 months) new york heart association functional class ii or iii symptoms, a left ventricular ejection fraction (lvef) ≤45% on maximally tolerated medical therapy (>3 months) and a 25(oh) vitamin d level of <50 nmol/l (<20 ng/ml)."
207,PMC4893154,S29,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population,"patients were ineligible if they were taking or had taken calcium or other vitamin supplements in the last 3 months; if their chronic hf was due to untreated valvular heart disease, anemia or thyrotoxicosis; if they had existing indications for vitamin d supplementation (e.g., previous osteoporotic fracture or symptoms of osteomalacia); if they had a history of primary hyperparathyroidism, sarcoidosis, tuberculosis or lymphoma, a cholecalciferol concentration at the time of screening >50 nmol/l (20 ng/ml); or if there was significant renal dysfunction (estimated glomerular filtration rate <30 ml/min)."
208,PMC4893154,S31,"['8b', '8a']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0]",Allocation and intervention,"patients enrolled into vindicate were allocated in blocks of 20 using minimization balancing for etiology of chronic hf (ischemic/non-ischemic), diabetes mellitus, sex, chronic obstructive pulmonary disease (requiring use of regular bronchodilators), and ethnic origin (caucasian/non-caucasian)."
209,PMC4893154,S32,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Allocation and intervention,"each participant was asked to take 2 tablets per day providing either a total of 100 μg cholecalciferol (4,000 iu daily) or placebo (cultech, port talbot, wales, united kingdom)."
210,PMC4893154,S33,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Allocation and intervention,the supplement and dose were chosen based upon guidelines for studies of vitamin d supplementation (17).
211,PMC4893154,S34,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Allocation and intervention,"these guidelines suggest that studies should: 1) aim to replace physiological requirements, supplementing between 75 and 250 μg/day; 2) last at least 9 months; 3) supplement with vitamin d3 (not d2); 4) assay supplements for potency; 5) include a regular serum measurement of 25(oh)d3 levels; and 6) aim to achieve serum levels in patients on active therapy between 100 and 160 nmol/l (40 ng/ml to 64 ng/ml)."
212,PMC4893154,S35,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Allocation and intervention,"also, on the basis of recent data demonstrating the adverse effect of hyperparathyroidism in chronic hf (18), we chose a dose likely to suppress parathyroid hormone (pth) release."
213,PMC4893154,S36,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Allocation and intervention,"our proof of concept study, using the same inclusion and exclusion criteria and protocol as vindicate, had previously demonstrated the efficacy of 4,000 iu daily to achieve positive remodeling with significant reductions in left ventricular end-diastolic volume (lvedv), left ventricular end-systolic volume (lvesv), and left ventricular end-diastolic dimension (lvedd)."
214,PMC4893154,S37,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Allocation and intervention,"the consort diagram and results from this study are presented in online supplementary datasets (online figure 1, online tables 1 and 2)."
215,PMC4893154,S38,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Allocation and intervention,"a simple linear model-based trend test from this study demonstrated a significant decrease in pth over the year (p = 0.0095) in those allocated vitamin d, with no such trend in patients allocated to the placebo arm (p = 0.977) (online figure 2) (19)."
216,PMC4893154,S40,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcome variables,the pre-specified primary endpoint in vindicate was the difference in change in 6-min walk test distance (6mwt) (baseline to 12 months) between the 2 groups.
217,PMC4893154,S41,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcome variables,"key pre-specified secondary endpoints included cardiac structure and function, and safety endpoints of serum calcium concentration, renal function, and vitamin d levels. hypervitaminosis d was defined as 25(oh)d3 >200 nmol/l (80 ng/ml), and hypercalcemia as >2.6 nmol/l (10.4 mg/dl)."
218,PMC4893154,S43,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study procedures,at baseline each patient performed a 6mwt according to standard criteria (20).
219,PMC4893154,S44,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study procedures,"each patient also underwent echocardiography and blood sampling for serum calcium, serum creatinine, vitamin d, and pth levels."
220,PMC4893154,S45,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study procedures,patients were also invited to undergo cardiac magnetic resonance (cmr) imaging to measure lv volumes.
221,PMC4893154,S46,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study procedures,"subsequent visits took place at 3, 6, 9, and 12 months and blood draws were repeated at each visit for safety data."
222,PMC4893154,S48,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Serum biochemistry,serum 25(oh)d2 and 25(oh)d3 were analyzed by tandem mass spectrometry.
223,PMC4893154,S49,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Serum biochemistry,samples were prepared using a protein precipitation reagent containing deuterated cholecalciferol.
224,PMC4893154,S50,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Serum biochemistry,"the supernatant was analyzed on an api5000 lc-ms/ms (ab sciex, warrington, united kingdom) in atmospheric-pressure chemical ionization mode."
225,PMC4893154,S51,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Serum biochemistry,the inter-assay coefficient of variability was <10% at all concentrations ranging from 12 nmol/l to 159 nmol/l (4.8 ng/ml to 63.7 ng/ml).
226,PMC4893154,S52,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Serum biochemistry,"ergocalciferol and cholecalciferol concentrations were summed and reported as total 25(oh)d. we defined deficiency and insufficiency of vitamin d concentrations as <50 nmol/l (20 ng/ml) and <75 nmol/l (30 ng/ml), respectively 21, 22."
227,PMC4893154,S53,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Serum biochemistry,"we also measured serum calcium, creatinine, and pth (siemens advia and centaur, siemens healthcare diagnostics, camberley, united kingdom)."
228,PMC4893154,S54,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Serum biochemistry,"to confirm effective conversion of the supplement, we also measured 1,25(oh)d3 by radioimmunoassay (ids, boldon, united kingdom) at baseline and 12 months."
229,PMC4893154,S56,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Echocardiography,echocardiography was performed on all patients at baseline and lv function was assessed according to european society of cardiology criteria using simpson’s biplane measure to determine lvef (23).
230,PMC4893154,S57,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Echocardiography,echocardiography was repeated at 12 months.
231,PMC4893154,S58,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Echocardiography,echocardiograms at both time points were analyzed offline at the end of the study by 2 senior echocardiographers blinded to patient treatment.
232,PMC4893154,S60,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",CMR imaging,"cmr studies were performed on dedicated 1.5-t or 3-t cmr systems (philips healthcare, best, the netherlands)."
233,PMC4893154,S61,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",CMR imaging,the same system was used for baseline and follow-up studies (at 12 months) of individual patients.
234,PMC4893154,S62,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",CMR imaging,"a multislice multiphase data set covering the entire left ventricle in 10 to 12 short axis slices was acquired using a validated 2-dimensional balanced steady-state free precession pulse sequence (tr 2.8 ms, te 1.4 ms, flip angle 55°, spatial resolution 2.0 mm × 2.0 mm × 10 mm, no interslice gap, 30 phases/cardiac cycle, 1 slice per breath-hold)."
235,PMC4893154,S63,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",CMR imaging,"offline analysis by an experienced cmr observer using qmass v7.0 software (medis, leiden, the netherlands) blinded to study allocation derived end-diastolic and end-systolic lv volumes and lvef."
236,PMC4893154,S65,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,vindicate was powered to provide information on the patient-oriented outcome of 6mwt.
237,PMC4893154,S66,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,a trial of iron supplementation in a similar patient group had demonstrated that improvements of 30 m to 40 m could be expected with this type of intervention (24).
238,PMC4893154,S67,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,"we assumed, based upon our preliminary data from a pilot study (19), that there would be a change between the 2 groups at 12 months of 30 m."
239,PMC4893154,S68,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,the sd of change in 6mwt was estimated from these data; the upper limit of the 80% confidence interval (ci) (estimated using bootstrapping) was used in these calculations to allow for the small sample size in the proof of concept.
240,PMC4893154,S69,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,this determined that 210 patients were required to have 90% power to show a difference in change in 6mwt of 28 m or more with 5% significance (sd = 62).
241,PMC4893154,S70,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,we aimed to recruit 230 patients (115 per group) to allow for ∼10% dropout.
242,PMC4893154,S72,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,differences in baseline variables between allocations were tested using student t tests (continuous data) or the chi-square test (categorical data).
243,PMC4893154,S73,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"the analysis of primacy for the main efficacy endpoints was based on analysis of covariance linear models relating differences in the final walk distance and imaging variables by treatment allocation, adjusting for baselines values and reported with 95% cis (25)."
244,PMC4893154,S74,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,all significance tests were 2-sided and called significant at the 5% level.
245,PMC4893154,S75,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"all analyses were conducted in stata (version 14, statacorp., college station, texas)."
246,PMC4893154,S77,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Ethical and safety considerations,a single unblinded observer with no involvement in the patients’ care or study follow-up (j.h.b.) reviewed each vitamin d result at each time point for safety.
247,PMC4893154,S78,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Ethical and safety considerations,an agreed operating procedure for any subject who developed a serum vitamin d concentration >200 nmol/l (80 ng/ml) involved reducing the dose of treatment from 2 to 1 tablets per day to maintain patient blinding.
248,PMC4902320,S160,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Supplementary Material,supplemental digital content
249,PMC4902320,S39,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,this was a randomized controlled trial.
250,PMC4902320,S40,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,the protocol was approved by the study hospital's human research ethics committee and registered with the australian new zealand clinical trials registry (actrn12611000387921).
251,PMC4902320,S41,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",METHODS,we randomly allocated participants (1:1) to either perioperative intravenous (iv) iron administration (intervention) or usual care.
252,PMC4902320,S42,['8a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0]",METHODS,randomization followed a computer-generated number sequence and allocation was conducted by telephone.
253,PMC4902320,S43,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,the surgeon performing the operation was informed of patient participation in the study but group allocation was not revealed.
254,PMC4902320,S44,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,we screened 626 patients scheduled for abdominal surgery for the presence of ida between august 2011 and november 2014.
255,PMC4902320,S45,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,"after informed written consent, patients eligible for inclusion (>18 yrs with ida, ferritin <300 mcg/l, transferrin saturation <25%, hb <12.0 g/dl for women, hb <13.0 g/dl for men) were randomized between 4 and 21 days before surgery into 2 groups."
256,PMC4902320,S46,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,"owing to this wide range in the preoperative period between patients, a standard approach was used to assess transfusion events in the preoperative period, including any transfusion administered in the 21 days before surgery."
257,PMC4902320,S47,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",METHODS,"patients in the intervention group received iv ferric carboxymaltose, given as a single dose over 15 minutes, before surgery (simplified dosing protocol; 15 mg/kg bodyweight to a maximum dose of 1000 mg)."
258,PMC4902320,S48,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",METHODS,"postoperatively, within 2 days of surgery, intervention group participants received 0.5 mg of ferric carboxymaltose per recorded 1 ml of blood loss, if blood loss was at least 100 ml."
259,PMC4902320,S49,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",METHODS,blood loss was measured as accurately as possible by recording suction bottle volume and weighing packs at the end of the operation.
260,PMC4902320,S50,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",METHODS,"patients in the usual care group received perioperative care, including anemia management, provided by the primary care physician or surgical home team."
261,PMC4902320,S51,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",METHODS,"usual care provided included no treatment, continued observations, oral iron recommendations, and abt."
262,PMC4902320,S52,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,"at the time of initiation of the study, iv iron was not considered usual care; however, prescription and administration was not disallowed."
263,PMC4902320,S53,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",METHODS,"in the institution, the prescription and administration of the intervention was facilitated by the anesthetic team."
264,PMC4902320,S54,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,baseline testing of the short form health survey (sf36) was conducted at study entry.28
265,PMC4902320,S55,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,follow-up of participants was scheduled for 4 weeks after surgery.
266,PMC4902320,S56,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,the sf36 and screening bloods were repeated at this time.
267,PMC4902320,S57,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",METHODS,"patients found to have noteworthy id or ida at follow-up, irrespective of group allocation, were referred to their general practitioner for ongoing management."
268,PMC4902320,S59,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Quality Control Procedure,a trial information session was given to the departmental members involved before commencing the study.
269,PMC4902320,S60,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Quality Control Procedure,regular refreshers were scheduled to assure protocol knowledge and adherence.
270,PMC4902320,S61,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Quality Control Procedure,the multidisciplinary composition of the research team facilitated this process.
271,PMC4902320,S62,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Quality Control Procedure,"follow-up and data entry were meticulously conducted by a research assistant, and primary care physician follow-up and care initiated when necessary to assure patient safety."
272,PMC4902320,S64,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,the primary endpoint was incidence of abt.
273,PMC4902320,S65,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"secondary endpoints included hemoglobin (hb) on admission, hb difference from randomization to admission, icu admission, perioperative morbidity (defined as new onset infection, respiratory failure, renal impairment, deep venous thrombosis), discharge hb, length of stay, hb at follow-up, hb difference from discharge to follow-up, iron status, 30-day mortality, and quality of life (qol)."
274,PMC4902320,S66,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"qol score was scaled from 36 to 160, with lower scores reflecting poorer well-being."
275,PMC4902320,S68,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical Analysis,the sample size of this study was calculated for the primary outcome parameter (perioperative allogeneic transfusion event).
276,PMC4902320,S69,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical Analysis,"to reduce the risk of a perioperative allogeneic transfusion event from 30% to 15% (a 50% risk reduction) with a power of β = 0.8 and a significance level of α = 0.05, it was determined that a total of 121 patients in each group would be needed."
277,PMC4902320,S70,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical Analysis,"to account for possible dropouts, we intended to include 134 patients per group."
278,PMC4902320,S71,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical Analysis,"the power calculation was performed using nquery advisor version 7.0 (statistical solutions, saugus, ma)."
279,PMC4902320,S72,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical Analysis,"parametric data were tested with one-way anova, and are presented as mean and standard error of the mean or as mean and 95% confidence intervals."
280,PMC4902320,S73,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical Analysis,"nonparametric data were tested with mann-whitney u tests, and are reported as either median (iqr) or median (minimum–maximum), as indicated."
281,PMC4902320,S74,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical Analysis,"categorical data were analyzed with the 2-tailed pearson χ2 test, and are presented accordingly as number and percent of total."
282,PMC4902320,S75,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical Analysis,"statistical analysis was performed using spss software version 17.0 (spss inc, chicago, il)."
283,PMC5009486,S44,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,male and female patients of 40–80 years of age with a diagnosis of copd as defined by the american thoracic society (ats) [11] and a smoking history of at least 10 pack-years were included in the study.
284,PMC5009486,S45,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"key lung function criteria for inclusion were pre- and post-short-acting bronchodilator (ipratropium bromide; atrovent® hfa) forced expiratory volume in 1 s (fev1)/forced vital capacity (fvc) ratio <0.7, post-bronchodilator fev1 ≥30 % and <80 % of the predicted value and ≥750 ml at screening (visit 1), and a pre-bronchodilator fev1 <80 % at randomization (visit 2) calculated using the third national health and nutrition examination survey (nhanes iii) reference equations [12]."
285,PMC5009486,S46,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"key exclusion criteria were diagnosis of asthma, α1-antitrypsin deficiency, or any other respiratory disease."
286,PMC5009486,S47,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,poorly controlled copd that had required hospitalization or treatment with systemic corticosteroids within 3 months or antibiotics within 6 weeks prior to screening (visit 1) also led to exclusion.
287,PMC5009486,S48,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"in addition, patients with clinically significant abnormal electrocardiogram (ecg) results; pregnant or lactating women; and patients who could not meet ats criteria for acceptable spirometry results were excluded [13]."
288,PMC5009486,S49,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Patients,"patients using oral β-agonists, inhaled labas, laba/ics combination inhalers, phosphodiesterase inhibitors, mast cell stabilizers, leukotriene antagonists, or tiotropium, discontinued these for the duration of the trial and instead received open-label ipratropium four times daily during the run-in period."
289,PMC5009486,S50,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Patients,"patients using ics/laba fdc inhalers who had received a stable dose for at least 4 weeks prior to screening were switched to the corresponding dose of a single ics agent, such as fluticasone, mometasone or budesonide administered bid for the remainder of the study."
290,PMC5009486,S51,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Patients,"patients receiving a maintenance dose of an ics that was not administered as a fdc were permitted to continue, provided they had been maintained on a stable dose for at least 4 weeks prior to screening."
291,PMC5009486,S52,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Patients,"other prohibited medications included non-selective β-receptor antagonists, tricyclic antidepressants, monoamine oxidase inhibitors, anticonvulsants, and phenothiazines."
292,PMC5009486,S54,"['3a', '4b']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and treatment,"this was a randomized, incomplete-block, crossover, placebo- (blinded) and active- (open-label) control study (nct01566773), conducted at 10 sites in the usa from 11 april 2012 to 10 august 2012."
293,PMC5009486,S55,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design and treatment,"six doses of gp mdi (18, 9, 4.6, 2.4, 1.2, and 0.6 μg), administered bid for 14 days, were assessed."
294,PMC5009486,S56,"['11b', '11a']","[0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and treatment,investigators and patients were blinded to gp mdi and placebo mdi treatment using non-distinguishable mdis.
295,PMC5009486,S57,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design and treatment,open-label tiotropium (18 μg; spiriva® handihaler®) dpi administered once daily (qd) was included as an active control.
296,PMC5009486,S58,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design and treatment,"in this study, gp is expressed as the salt, glycopyrrolate (glycopyrronium bromide), where a dose of 18 μg is equivalent to 14.4 μg glycopyrronium (active moiety)."
297,PMC5009486,S59,['8a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0]",Study design and treatment,"following screening, patients were randomized using an interactive web response system to one of 120 pre-defined treatment sequences, comprising four out of the eight possible treatments."
298,PMC5009486,S60,"['5', '3a']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design and treatment,"each treatment period was 14 days, separated by a 7- to 21-day washout period (fig. 1)."
299,PMC5009486,S61,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and treatment,fig. 1 study design schematic.
300,PMC5009486,S62,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and treatment,rand randomization; pft pulmonary function test; rx treatment
301,PMC5009486,S63,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and treatment,"at each study visit and prior to performing any study procedures, patients had to confirm that they had withheld all copd medication for at least 6 h, or the visit was rescheduled as soon as practical and within the specified visit windows."
302,PMC5009486,S64,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design and treatment,"during the study, albuterol sulfate (salbutamol hfa; ventolin®) mdi was permitted as needed for relief of symptoms."
303,PMC5009486,S65,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design and treatment,"during screening and washouts between treatment periods, ipratropium bromide (atrovent® hfa) mdi was used as maintenance medication."
304,PMC5009486,S66,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and treatment,"this study was conducted in accordance with international conference on harmonization guidelines, the declaration of helsinki [14], and the us code of federal regulations."
305,PMC5009486,S68,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"patients attended scheduled clinic visits at screening (visit 1), randomization (visit 2), then on days 1, 7, and 14 of each treatment period."
306,PMC5009486,S69,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"all pulmonary function tests, including fev1, fvc and inspiratory capacity (ic) as defined in ats guidelines, were performed in accordance with ats criteria [13]."
307,PMC5009486,S70,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,spirometry was performed to assess lung function pre- and post-dose at each study visit.
308,PMC5009486,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"the assessed time points on days 1 and 7 of each treatment period were 60 and 30 min pre-dose and 15, 30, 60, and 120 min post-dose."
309,PMC5009486,S72,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"on day 14, post-dose time points were assessed up to 12 h post-dose."
310,PMC5009486,S73,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"safety evaluations included heart rate, diastolic blood pressure, and ecgs, conducted at every clinic visit."
311,PMC5009486,S74,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,blood samples were taken pre- and post-dose on days 1 and 14 of each treatment period to perform laboratory assessments including hematology and blood chemistry.
312,PMC5009486,S75,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"adverse events (aes) and serious aes were documented by investigators, with paradoxical bronchospasm and dry mouth classified as events of interest."
313,PMC5009486,S77,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Endpoints,the primary objective of this study was to assess efficacy relative to placebo mdi of gp mdi.
314,PMC5009486,S78,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Endpoints,"to this end, each dose of gp mdi was compared with placebo mdi on the primary efficacy endpoint; fev1 area under the curve from 0 to 12 h (auc0–12) relative to baseline on day 14 of each treatment period."
315,PMC5009486,S79,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Endpoints,fev1 auc0–12 values were normalized by dividing by the length of time over which they were obtained (typically 12 h).
316,PMC5009486,S80,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Endpoints,"the key secondary endpoints were time to onset of action (≥10 % improvement from baseline in fev1) on day 1; peak change from baseline in fev1 on days 1, 7, and 14; change from baseline in morning pre-dose trough fev1 on days 7 and 14; change from baseline in 12-h post-dose trough fev1 on day 14; peak change from baseline in ic on days 1, 7, and 14; mean change from baseline in morning pre-dose trough ic on days 7 and 14; and the proportion of patients achieving ≥12 % improvement in fev1 on day 1."
317,PMC5009486,S82,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,"the planned sample size was 120 patients, designed to provide approximately 93 % power to detect differences of 100 ml in fev1 auc0–12."
318,PMC5009486,S83,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,"the 100-ml difference was selected on the grounds that it is the minimum clinically important difference, defined as the change in fev1 that can be perceived by the patient [15]."
319,PMC5009486,S84,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,"the principal population for primary efficacy analyses was the modified intent-to-treat (mitt) population, comprising all patients who completed at least two treatment periods with at least 2 h of post-dose data for day 14 from both periods."
320,PMC5009486,S85,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,"for the primary efficacy analysis of assessing the dose–response curve, the family-wise type i error was not controlled for multiplicity beyond specifying a primary endpoint and the six key comparisons, namely each dose of gp mdi compared with placebo mdi."
321,PMC5009486,S86,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"to compare each dose of gp mdi with placebo mdi, a linear mixed-effects model was used with fev1 auc0–12 as the dependent variable, and baseline trough fev1, bronchodilator reversibility, period, sequence, and treatment as covariates."
322,PMC5009486,S87,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,baseline was defined as the mean of pre-dose values obtained from the first day of each treatment cycle averaged across periods.
323,PMC5009486,S88,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,secondary efficacy analysis for the primary efficacy endpoint assessed the non-inferiority of each treatment group to open-label tiotropium using a margin for clinical relevance of 100 ml.
324,PMC5009486,S89,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,other secondary efficacy analyses involved superiority comparisons of secondary endpoints for each treatment group versus placebo mdi and non-inferiority comparisons versus open-label tiotropium.
325,PMC5009486,S90,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,non-inferiority was only determined for a treatment group if the lower bound of the 95 % confidence interval (ci) for the difference was above −100 ml and if all higher dose levels were statistically significantly non-inferior to open-label tiotropium.
326,PMC5009486,S91,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"non-inferiority testing was not performed for time to onset of action on day 1, for which cumulative incidence kaplan–meier curves were plotted."
327,PMC5009486,S92,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,the proportion of patients achieving ≥12 % improvement from baseline on day 1 was tabulated and a logistic regression was used to compare treatments.
328,PMC5009486,S93,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"for safety analyses the safety population was used, defined as all patients who were randomized and received at least one dose of study treatment and had a post-baseline safety assessment for that treatment."
329,PMC5009486,S94,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"safety and tolerability data, including laboratory parameters, vital signs and ecg results were summarized descriptively, with aes tabulated according to severity, relationship to study drug and the medical dictionary for regulatory activities system level and preferred term."
330,PMC5033259,S31,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Research Design and Methods,"forty-eight men and women provided written informed consent to participate in this randomized, placebo-controlled, double-blind study (full details are available in supplementary fig. 1)."
331,PMC5033259,S32,['4b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Research Design and Methods,participants first had a screening visit at the beth israel deaconess medical center clinical research center to ensure that they met the inclusion and exclusion criteria for the study.
332,PMC5033259,S33,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Research Design and Methods,no prior studies with lorcaserin in the human brain existed on which to base power calculations.
333,PMC5033259,S34,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Research Design and Methods,"we thus enrolled 48 subjects, with an a priori plan to replace up to 8 subjects that would drop out (assuming up to 20% attrition)."
334,PMC5033259,S35,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Research Design and Methods,sample size was selected to be similar to prior randomized trials of other pharmaceuticals studied using similar neuroimaging protocols.
335,PMC5033259,S36,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Research Design and Methods,"with 80% power and 2 groups of 20 participants, we estimated that we would be able to detect an effect size difference of 0.9 at the α = 0.05 level."
336,PMC5033259,S37,"['11b', '5']","[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Research Design and Methods,"after the screening visit, participants were randomized 1:1 to receive oral lorcaserin (10 mg, twice daily) or placebo, which was identical in appearance to lorcaserin."
337,PMC5033259,S38,"['8a', '8b', '11a', '10']","[0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0]",Research Design and Methods,randomization tables were produced by the harvard catalyst biostatisticians with sas using blocks of four and delivered directly to the research pharmacy for use such that study staff would remain blinded.
338,PMC5033259,S39,['4b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Research Design and Methods,"the study took place over 4 weeks; participants visited the clinical research center on weeks 0, 1, 2, and 4."
339,PMC5033259,S40,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Research Design and Methods,"the first study visit was a baseline overnight visit, which consisted of at least a 12-h fast, followed by a blood draw, vital signs, physical examination, anthropometry (waist and hip measurements), resting metabolic rate (measured with sensormedics vmax spectra), two fmri scans (one in the fasting state and another in the fed state), and neurocognitive testing."
340,PMC5033259,S41,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Research Design and Methods,"in addition, at each visit, all participants were given the standard of care for obesity, where they met with a registered dietitian to be counseled about weight loss, with the recommendation of decreasing caloric intake by 500 kcal/day and exercising 30 min 3 days/week."
341,PMC5033259,S42,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Research Design and Methods,"patients were also given the modified scale for suicidal ideation (mssi) by a physician at each visit to ensure they did not develop suicidal thoughts, because manipulating serotonin levels could potentially lead to changes in mood and suicidal ideation."
342,PMC5033259,S43,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Research Design and Methods,they returned after 1 and 4 weeks for the same overnight visits.
343,PMC5033259,S44,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Research Design and Methods,"participants also attended an outpatient follow-up visit at 2 weeks, which consisted of a physical examination and blood draw."
344,PMC5033259,S45,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Research Design and Methods,"in between visits, patients continued to take their medication at home and kept a detailed food diary, which was discussed with the patients at each visit and analyzed by registered dietitians."
345,PMC5033259,S46,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Research Design and Methods,fasting blood was drawn by venipuncture by a registered nurse.
346,PMC5033259,S47,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Research Design and Methods,"samples were analyzed by labcorp, a clinical laboratory improvement amendments–certified laboratory."
347,PMC5033259,S49,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data Analysis,data were analyzed using spss 19 software and first summarized with descriptive statistics.
348,PMC5033259,S50,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data Analysis,data for categorical variables are presented as numbers and/or percentages.
349,PMC5033259,S51,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data Analysis,kolmogorov-smirnov test and frequency histograms were used to check the normality of distribution of the continuous variables.
350,PMC5033259,S52,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data Analysis,repeated-measures anova were performed across time points with lorcaserin or placebo as a between-subjects factor.
351,PMC5033259,S53,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data Analysis,on-treatment analysis was performed for all variables (results reported in table 1).
352,PMC5033259,S54,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data Analysis,"intention-to-treat analysis was done with the anthropometric data only, to confirm on-treatment analysis, using the last observation carried forward method (results reported in table 2)."
353,PMC5033259,S55,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data Analysis,table 1 results from study visits over 1 month for the lorcaserin (n = 17) and placebo (n = 19) groups
354,PMC5033259,S56,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data Analysis,table 2 results from study visits over 1 month for the lorcaserin (n = 24) and placebo (n = 24) groups using intent-to-treat methods
355,PMC5033259,S58,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,participants viewed food and nonfood items within a 3-tesla ge mri scanner at the mri center at beth israel deaconess medical center in the fasting and fed states with an invivo therapeutics 8-channel high-definition receiver head coil.
356,PMC5033259,S59,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,scanning was done using a protocol similar to that previously described (18).
357,PMC5033259,S60,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,"first, in each of the scanning sessions, a t1-weighted magnetization prepared rapid gradient echo structural mri was acquired."
358,PMC5033259,S61,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,"next, five 7-min gradient-echo t2-weighted echo planar images depicting blood oxygenation level–dependent (bold) contrast were acquired from noncontiguous near axial planes (repetition time = 3.5 s, echo time = 25 ms, in-plane resolution = 2.5 × 2.5 mm, matrix size = 96 × 96, field of view = 24 × 24 cm, voxel bandwidth = 83.33 khz, slice thickness = 3 mm)."
359,PMC5033259,S62,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,e-prime software controlled stimulus presentation.
360,PMC5033259,S63,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,"images were presented in blocks, and each block was presented in a counterbalanced order and interspersed with periods of visual fixation."
361,PMC5033259,S64,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,"the fmri protocol consisted of five runs, during which subjects viewed blocks of highly desirable (high-calorie or high-fat images such as cakes, onion rings, and other similar foods), less desirable (low-calorie or low-fat images such as vegetables and fruits), or nonfood images (examples included flowers, rocks, and trees) and provided responses on how well they could imagine or visualize each image using a response box held in their right hand, as previously described (19,20)."
362,PMC5033259,S65,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,"approximately 150 images were used in randomized order, presented during both the fasting and fed states."
363,PMC5033259,S66,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,"blocks consisted of 5 images each, where each image was shown for 3 s (15 s total for each block), with 10 s of fixation/rest between blocks, and 16 blocks were shown during each of the 5 runs."
364,PMC5033259,S67,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,"bold data were preprocessed using spm8 software (statistical parametric mapping; the wellcome trust centre of neuroimaging, london, u.k.)."
365,PMC5033259,S68,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,"briefly, images of each individual subject were flipped, realigned (motion-corrected), normalized to an epi template with affine registration, followed by nonlinear transformation, and smoothed with a gaussian kernel of 6 mm."
366,PMC5033259,S69,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,"a general linear model was constructed for each subject, using the onsets of the food or nonfood image blocks with realignment parameters in six dimensions."
367,PMC5033259,S70,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,the data were high-pass filtered to remove low-frequency signal drifts.
368,PMC5033259,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,the contrast images (highly desirable > less desirable food images; all food (highly and less desirable) > nonfood images) of the first-level analysis were used for the second-level group statistics.
369,PMC5033259,S72,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,"flexible factorials were used to compare the two groups at weeks 1 and 4, controlling for baselines (week 0)."
370,PMC5033259,S73,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,"whole-brain regressions were used to examine how brain activations at baseline (week 0) related to changes in weight, bmi, and caloric intake."
371,PMC5033259,S74,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,"given the multiple areas studied, activations that passed a corrected threshold of p < 0.05, family-wise error (fwe) corrected for multiple comparisons for the cluster, and/or peak activation are reported."
372,PMC5033259,S75,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,"on the basis of an a priori hypothesis for the hypothalamus, owing to findings in rodents of lorcaserin’s weight-reducing efficacy being mediated by the hypothalamus, we performed a region of interest analysis for the hypothalamus using a 10-mm radius sphere, as defined previously (19)."
373,PMC5033259,S76,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,"effect size data for hypothalamus and for activations, which were significantly different for week 1 > week 0 and for week 1 > week 4, contrasts were extracted using marsbar (http://marsbar.sourceforge.net/)."
374,PMC5033259,S77,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,effect sizes were examined between groups and over time for the hypothalamus.
375,PMC5033259,S78,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,effect sizes from contrasts were correlated with changes in bmi and caloric intake using pearson correlations.
376,PMC5064025,S44,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,"novartis pharmaceuticals (cambridge, massachusetts) initiated this phase ii, double-blind, randomized, placebo-controlled trial, with the final study protocol designed in collaboration with the investigators (r.p.c., j.-c.t., and z.a.f.), based on their previously published methods 19, 23, 24."
377,PMC5064025,S45,['4b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,"the study was undertaken at 9 centers in canada, the united kingdom, the united states, germany, and israel, in compliance with the principles of the declaration of helsinki and according to good clinical practice guidelines."
378,PMC5064025,S46,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,"the protocol was reviewed and approved by the institutional review board, or equivalent, for each center."
379,PMC5064025,S47,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,all participants provided written informed consent before undertaking any study procedures.
380,PMC5064025,S49,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,patients (ages 18 to 74 years) were eligible for inclusion if they had clinically evident atherosclerotic vascular disease: previous myocardial infarction; history of angina; carotid stenosis (>30%); peripheral vascular disease (ankle–brachial index <0.9); endarterectomy >3 months previously; or transient ischemic attack or stroke.
381,PMC5064025,S50,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"in addition, patients must also have had either t2dm (for ≤14 years and glycosylated hemoglobin [hba1c] levels between 6% and 10%) or igt (defined as a peak 2-h glucose reading ≥140 mg/dl but <200 mg/dl after an oral glucose tolerance test during screening)."
382,PMC5064025,S51,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,patients were to have been on stable statin therapy for a period of ≥6 weeks before screening (or have physician-documented statin intolerance).
383,PMC5064025,S52,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Patients,"after consent, eligible patients were randomized (1:1) to receive canakinumab 150 mg or placebo, subcutaneously, monthly for 12 months."
384,PMC5064025,S53,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"exclusion criteria included: pregnancy; systemic steroid use; baseline high-sensitivity c-reactive protein (hs-crp) levels >30 mg/l; history of significant multiple drug allergies; history or evidence of chronic infection, including tuberculosis and liver disease; or a standard contraindication to mri."
385,PMC5064025,S54,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,randomization occurred between december 2009 and november 2012.
386,PMC5064025,S55,"['8a', '8b', '10']","[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0]",Patients,"patient groups were assigned centrally according to a validated computer-generated randomization code, stratified according to glycemic status (t2dm or igt)."
387,PMC5064025,S57,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Imaging procedures,an integrated vascular mri was performed at baseline and after 3 and 12 months of treatment.
388,PMC5064025,S58,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Imaging procedures,"if the imaging data did not meet an evaluable standard at any time point, the patient was rescanned."
389,PMC5064025,S59,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Imaging procedures,randomization required an evaluable baseline scan.
390,PMC5064025,S60,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Imaging procedures,"the imaging procedure comprised measures of aortic wall area and distensibility, as well as carotid wall area bilaterally."
391,PMC5064025,S61,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Imaging procedures,"the imaging protocol was adapted from lee et al. (19), and staff at each imaging site underwent individualized training to ensure consistency of method and data acquisition."
392,PMC5064025,S62,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Imaging procedures,"all trial sites used a 3.0-t whole-body mri scanner, including trio, tim trio, or verio (siemens medical solutions usa, inc., malvern, pennsylvania) or achieva (philips, amsterdam, the netherlands) platforms."
393,PMC5064025,S63,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Imaging procedures,"for carotid imaging, a bilateral 4-channel carotid array (machnet b.v., roden, the netherlands) was used on the siemens scanners and an equivalent multi-channel (4 to 8) phased array carotid coil (shanghai medical, shanghai, china) was used on the philips scanners."
394,PMC5064025,S64,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Imaging procedures,detailed information regarding imaging protocols and analysis is available in the online appendix.
395,PMC5064025,S65,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Imaging procedures,the velocity at which the arterial pulse propagates is termed pulsed wave velocity (pwv).
396,PMC5064025,S66,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Imaging procedures,"a measure of arterial stiffness, it is an independent predictor of mortality in both t2dm and igt (26)."
397,PMC5064025,S67,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Imaging procedures,the sphygmocor platform (atcor medical pty.
398,PMC5064025,S68,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Imaging procedures,"ltd., west ryde, australia) was applied immediately before mri scanning to acquire the aortic central pulse pressure from radial artery applanation tonometry and the pwv from the carotid-femoral pulse waves."
399,PMC5064025,S70,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Safety assessments,"monitoring of vital signs, electrocardiogram, standard hematology, and biochemistry (including measurement of lipoproteins, liver function, and creatine kinase) were conducted throughout the study."
400,PMC5064025,S71,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Safety assessments,a data monitoring committee oversaw subject safety on an ongoing basis.
401,PMC5064025,S72,"['6a', '11a']","[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Safety assessments,"in addition, 3 adjudication committees made blinded assessments of adverse events in relation to cardiac, malignant, and infection-related events."
402,PMC5064025,S74,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Endpoints,the primary efficacy objectives were the effects of the drug on aortic distensibility and total plaque burden in the aorta and carotid arteries; the primary safety objective was the safety and tolerability of canakinumab in this population.
403,PMC5064025,S75,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Endpoints,secondary objectives included the effects of canakinumab on aortic pwv; hs-crp; hba1c; homeostasis model assessment (homa)–insulin resistance; and peak blood glucose level 2 h after an oral glucose challenge.
404,PMC5064025,S76,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Endpoints,"exploratory analyses of peripheral biomarkers of inflammation (including il-6, serum amyloid a, and plasma lipoproteins) were also performed."
405,PMC5064025,S78,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,sample size was calculated from the study of lee et al. (19).
406,PMC5064025,S79,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analyses,"to detect a 35% change in aortic distensibility or an 11% change in plaque burden at 12 months to achieve a power of 0.8 and nominal p < 0.05 (2-sided), 60 patients per group were required."
407,PMC5064025,S80,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analyses,"to ensure 120 datasets with 12-month follow-up data, it was planned to randomize 190 patients."
408,PMC5064025,S81,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"given the exploratory nature of the study, corrections were not made for the multiplicity of statistical tests."
409,PMC5064025,S82,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"as defined by the protocol, patients were included in the 3-month data analysis if they had no missing doses at 3 months; for the 12-month analysis, participants were required to have no missing doses by 3 months and 1 or no missing doses between 3 and 12 months."
410,PMC5064025,S83,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"to compare treatment with placebo, we conducted an analysis of covariance on change from baseline, including the glycemic status as a factor and the baseline as a covariate at 3 and 12 months."
411,PMC5064025,S84,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"all data were checked for normality and log-transformed, if appropriate."
412,PMC5064025,S85,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"when a log transformation of the change from baseline was not possible because of negative values, an analysis of covariance was conducted on the log-transformed 3- and 12-month data, including glycemic index status as a factor and the log-transformed baseline as a covariate."
413,PMC5064025,S86,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,we considered a p value <0.05 as significant.
414,PMC5064025,S87,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,results are reported as means with 95% confidence limits.
415,PMC5064025,S88,['7b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0]",Statistical analyses,"two interim analyses were pre-specified, when n = 60 and all patients had completed 3 months of treatment, respectively, with the intention of halting the study if adverse measures were identified or for futility but not for interim positive efficacy."
416,PMC5064025,S89,['7b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0]",Statistical analyses,the interim analyses were performed by independent personnel not directly associated with the study’s conduct.
417,PMC5064025,S90,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,the study sponsor and funder (novartis) participated in discussions about the design and conduct of this study; they also provided the drugs used in the trial and logistical support for its execution.
418,PMC5064025,S91,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"the trial design, endpoints, and statistical analyses were largely derived from the academic investigators’ previously published studies 19, 23, 24."
419,PMC5064025,S92,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"following the final database lock, all patient data were analyzed independently by the centre for statistics in medicine, oxford (j.b.)."
420,PMC5064025,S93,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"the manuscript was drafted by the academic investigators (r.p.c., j.s.b., j.-c.t., and z.a.f.), in accordance with the written agreement between novartis and the academic institutions, and reviewed and revised by the writing committee."
421,PMC5064025,S94,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,all authors had full access to all the data in the study and assume responsibility for publication.
422,PMC5064025,S95,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"all statistical analyses were performed by using stata 14 (statacorp lp, college station, texas)."
423,PMC5099201,S147,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Supplementary Material,web supplement
424,PMC5099201,S38,"['4a', '3a']","[0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and participants,"n this randomised, controlled study, patients with ra diagnosed according to the 1987 american college of rheumatology (acr) criteria less than 10 years before, aged between 20 and 75 years, with moderate or high disease activity at baseline visits, were enrolled between november 2009 and march 2012."
425,PMC5099201,S39,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and participants,"moderate or high disease activity was defined as a disease activity score in 28 joints (das28; on the basis of the erythrocyte sedimentation rate, esr) of more than 3.2."
426,PMC5099201,S40,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and participants,participants had to have been receiving stable doses of ≥6 mg/week of mtx for treatment of ra for at least 8 weeks before enrolment.9
427,PMC5099201,S41,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and participants,"patients were excluded if they had previously taken or were taking any biologic treatment, leflunomide within 12 weeks of baseline, tacrolimus within 4 weeks, or any other conventional dmards other than mtx within 8 weeks."
428,PMC5099201,S42,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and participants,patients taking prednisolone (or equivalent) at a dose of more than 10 mg/day were excluded.
429,PMC5099201,S43,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and participants,"this report covers the planned analysis of the first 1 year of a 2-year study (nct01120366, umin000002744)."
430,PMC5099201,S44,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and participants,this study was approved by the ethics committee at each site and conducted in accordance with the declaration of helsinki.
431,PMC5099201,S45,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and participants,"all participants gave their written, informed consent."
432,PMC5099201,S47,"['3a', '5', '8a']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0]",Study treatment,patients were randomly assigned by a centralised system in a 1:1 ratio to one of two open-label treatment groups: tcz added to mtx (add-on group) or tcz switched from mtx (switch group).
433,PMC5099201,S48,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study treatment,"tcz was administered at a dose of 8 mg/kg intravenously every 4 weeks, and mtx was maintained at the same dose as the baseline unless a clinically relevant adverse event (ae) occurred."
434,PMC5099201,S50,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Collected patient data and assessments,data collected at baseline included demographics and disease characteristics.
435,PMC5099201,S51,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Collected patient data and assessments,"the following parameters were assessed at baseline and at weeks 4, 12, 24, and 52: tender joint count, swollen joint count, health assessment questionnaire-disability index, patient global assessment using a visual analogue scale (vas), evaluator global assessment using a vas, c-reactive protein (crp), esr and matrix metalloproteinase-3."
436,PMC5099201,S52,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Collected patient data and assessments,radiographs of the hands and feet were obtained at baseline and at week 52.
437,PMC5099201,S53,"['6a', '11a']","[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Collected patient data and assessments,each radiograph was assessed applying the van der heijde-modified total sharp scoring system (mtss) by two independent readers who were blinded to treatment assignment and the patient's clinical status.
438,PMC5099201,S54,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Collected patient data and assessments,"at each visit, patients were monitored for physical signs, laboratory tests, and aes."
439,PMC5099201,S56,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,the primary outcome of this study was defined as the percentage of patients in remission according to the das28-esr at week 24.
440,PMC5099201,S57,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,"with the assumption that das28-esr remission would be achieved by 50% of patients in the add-on group and 45% in the switch group, 133 patients per treatment group were calculated as necessary for more than 80% power to prove the null hypothesis of no difference between the treatment arms with a non-inferiority margin of 10%."
441,PMC5099201,S58,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,a two-sided statistical test of no difference at the 5% significance level was used.
442,PMC5099201,S59,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,"as a sensitivity analysis, the percentage of patients in remission according to the simplified disease activity index (sdai) and clinical disease activity index (cdai) in substitution for the das28 was further analysed."
443,PMC5099201,S60,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,efficacy analyses were conducted in the full analysis population with the last-observation-carried-forward method.
444,PMC5099201,S61,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,"safety endpoints including the incidence of aes, serious aes, infections, and specific laboratory abnormalities were analysed in all treated patients."
445,PMC5099201,S62,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"all analyses of proportions were analysed for treatment differences with the χ2 test, and continuous variables were compared with student's t test."
446,PMC5264229,S188,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Supplementary Material,web supplement
447,PMC5264229,S39,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,patients who were 18–75 years old with ra classified by the 1987 american college of rheumatology (acr) classification criteria for ra were enrolled; patients had to have had ra for at least 6 months with least six tender joints and six swollen joints; an erythrocyte sedimentation rate (esr) of ≥28 mm/h or a c reactive protein of ≥1.0 mg/dl was required.
448,PMC5264229,S40,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,patients had to take mtx for at least 6 months and had to be under a stable dose for at least 4 weeks before randomisation.
449,PMC5264229,S41,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"for details of inclusion and exclusion criteria, see online supplementary appendix s1."
450,PMC5264229,S43,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"this study is a phase iii, randomised, double-blind, multinational, multicentre parallel group study (nct01936181, eudract 2012-005733-37)."
451,PMC5264229,S44,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"the study consists of a 54-week main study and an additional 24-week transition (switching) study; this report is about the results of the 54-week main study up to week 30 (for the graphical presentation see online supplementary appendix s2-1), which includes the primary outcome."
452,PMC5264229,S45,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,patients were randomised in a 1:1 ratio to receive either sb2 or inf of 3 mg/kg intravenously.
453,PMC5264229,S46,"['10', '8a']","[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0]",Study design,"randomisation and treatment allocation was implemented through an interactive web responsive system (cenduit llc, see online supplementary appendix s3-1)."
454,PMC5264229,S47,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,"infusion of sb2 or inf was done over 2 h; dosing was done at each visit at week 0, week 2, week 6, week 14, week 22, week 30, week 38 and week 46."
455,PMC5264229,S48,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,"dose increases could occur from week 30 by 1.5 mg/kg per visit, up to a total of 7.5 mg/kg."
456,PMC5264229,S49,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,the final visit for the main study occurred at week 54.
457,PMC5264229,S50,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,"to prevent infusion related reactions (irrs), premedications such as corticosteroids, antihistamines or paracetamol were allowed per investigator discretion."
458,PMC5264229,S51,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,mtx was given as an oral or parenteral weekly dose of 10–25 mg/week with folic acid of 5–10 mg/week.
459,PMC5264229,S52,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,non-steroidal anti-inflammatory drugs and corticosteroids (≤10 mg prednisolone) were allowed if taken for a stable dose for 4 weeks before randomisation.
460,PMC5264229,S53,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,other disease modifying antirheumatic drugs except for mtx were prohibited during the study.
461,PMC5264229,S54,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"all patients were screened for tuberculosis (tb) by medical history, chest x-ray and quantiferon-tb gold in-tube tests (qiagen); quantiferon tests were done at screening, week 22 and week 54."
462,PMC5264229,S55,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,patients with active tb were ineligible for the study and those who were found to have latent tb had to undergo prophylaxis according to country-specific guidelines to enrol in or continue with the study.
463,PMC5264229,S56,['4b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,the study was conducted in 73 centres in 11 countries from europe and asia.
464,PMC5264229,S57,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,the study was conducted according to the declaration of helsinki and good clinical practice issued by the international committee on harmonisation.
465,PMC5264229,S58,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,all patients gave formal written informed consent before participating in the study.
466,PMC5264229,S60,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"efficacy, safety and immunogenicity assessments for all patients were done at each visit before sb2 or inf infusion."
467,PMC5264229,S61,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,the primary end point of the study was the acr 20% (acr20) response at week 30 in the per-protocol set (pps).
468,PMC5264229,S62,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"other secondary efficacy end points included acr50 and acr70, disease activity score measured by 28 joints-erythrocyte sedimentation rate (das28-esr) and european league against rheumatism (eular) response."
469,PMC5264229,S63,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,a post hoc analysis of simplified disease activity index (sdai) and clinical disease activity index (cdai) was done to measure the proportion of patients achieving low disease activity (lda) or remission.15 16
470,PMC5264229,S64,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"efficacy components such as tender and swollen joint counts, visual analogue scales scores and health assessment questionnaire of disability index scores were assessed before each infusion."
471,PMC5264229,S65,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"safety assessments included monitoring of vital signs, physical examination, laboratory assessments and reports of adverse events (aes)."
472,PMC5264229,S66,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"aes were collected in particular for serious aes, serious infections or tb and irrs."
473,PMC5264229,S67,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,immunogenicity assessments were done by measuring serum antidrug antibodies (adas) to infliximab at each visit before infusion.
474,PMC5264229,S68,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,ada-positivity was defined as those who had at least one positive ada result up to week 30.
475,PMC5264229,S69,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Assessments,"this was a prespecified outcome, according to recommendations from the american association of pharmaceutical scientists.17"
476,PMC5264229,S70,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Assessments,it accommodates all measures of ada incidence over each individual time point that may be subject to variation.
477,PMC5264229,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,those who were ada-positive were additionally assessed for neutralising antibodies.
478,PMC5264229,S72,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,a single-assay approach with a sb2 tag was used to assess immunogenicity.
479,PMC5264229,S73,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"adas were measured using validated electrochemiluminescence immunoassays and neutralising antibodies were measured using a competitive ligand-binding assay (mesoscale discovery platform, meso scale discovery, rockville, maryland, usa)."
480,PMC5264229,S74,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,pk assessments were done by measuring the serum trough concentrations (ctrough) of infliximab before each infusion.
481,PMC5264229,S75,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,serum infliximab concentrations were determined using a validated elisa.
482,PMC5264229,S77,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,the primary objective was to demonstrate equivalence of acr20 at week 30.
483,PMC5264229,S78,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size and statistical analysis,to determine equivalence between sb2 and inf the 95% ci of the acr20 rate difference had to be within the prespecified margin of −15% and +15%.
484,PMC5264229,S79,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size and statistical analysis,the equivalence margin was determined using data from several inf studies4 18 19 and regulatory guidelines.20 21
485,PMC5264229,S80,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size and statistical analysis,"sample size was calculated assuming this equivalence margin of ±15%, an effect size of 57% and a 20% dropout rate."
486,PMC5264229,S81,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size and statistical analysis,"with a significance level of 5% and a power of 80%, a sample size of at least 292 randomised patients per treatment group was required in order to reach the required subject size for the pps."
487,PMC5264229,S82,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,the primary efficacy outcome was analysed using the pps and the full analysis set (fas).22
488,PMC5264229,S83,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,fas follows the same principles of the intention-to-treat analysis; fas included all randomised patients who received at least one dose of sb2 or inf.
489,PMC5264229,S84,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,"in addition, if missing data occurred, such patients were assumed to be acr20 non-responders in fas."
490,PMC5264229,S85,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,"for analysis of acr20, the rate difference was adjusted by baseline c reactive protein and geographical region using a non-parametrical analysis of covariance.23–25"
491,PMC5264229,S86,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,"analysis of acr50 and acr70 was also done in pps and fas; das28, sdai, cdai and eular response were done only in the fas (only available das28 and sdai/cdai were analysed in this case)."
492,PMC5264229,S87,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,subgroup analysis of acr20 was done by comparing acr20 response rates within each ada subgroup (positive or negative) in a prespecified manner.
493,PMC5264229,S88,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,"to formally test the differential influence of ada on sb2 or inf, an analysis of covariance was done including an ada-by-treatment interaction term in the model."
494,PMC5264229,S89,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,a prespecified exponential time-response model using non-linear mixed models26 was fitted to compare the acr20 response between sb2 and inf over time (see also online supplementary appendix s3-2).
495,PMC5264229,S90,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,"the squared differences across all time points from the two curves (2-norm) were measured, and if the upper limit of the 95% ci of the 2-norm was less than 61.80, the two curves were considered equivalent."
496,PMC5264229,S91,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,safety results were presented as the number of patients with percentage who had a particular ae in the safety analysis set (saf; those who received at least one dose of sb2 or inf).
497,PMC5264229,S92,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,immunogenicity results were presented as the number of patients with percentages having incident ada up to week 30 from the saf.
498,PMC5264229,S93,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,pk assessment was done in the pk population (approximately the first enrolled 50% of the study population) up to week 30.
499,PMC5264229,S94,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,pk results are shown as mean ctrough with sd and coefficient of variation from the pk population.
500,PMC5264229,S95,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,"general statistical analysis was done using sas v.9.2 (sas, cary, north carolina, usa)."
501,PMC5264229,S96,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,"pk parameters were calculated by non-compartmental analyses (winnonlin v.5.2, pharsight, mountain view, california, usa)."
502,PMC5264229,S97,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,graphical figures were made using r 3.0.1 (http://www.r-project.org).
503,PMC5418559,S39,"['3a', '4b']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"this was a multicenter, phase 2, randomized, double-blind, placebo-controlled study conducted at 79 sites in the usa (clinicaltrials.gov identifier: nct01923428) between august 2013 and october 2014 (last patient last visit july 2014)."
504,PMC5418559,S40,['4b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,the sites conducting the study were gastroenterology practices (n=26) or primary care and research practices (n=53) specializing in internal medicine and/or gastroenterology.
505,PMC5418559,S41,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,"after a 2-week screening period, eligible patients were randomly assigned in a 1:1:1:1 ratio to one of four treatment groups: tenapanor 5 mg, 20 mg, or 50 mg twice daily (b.i.d.; dosed as the hydrochloride salt) or placebo b.i.d. patients received tenapanor or placebo for 12 consecutive weeks, after which they were followed up for an additional 4 weeks."
506,PMC5418559,S42,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"patients visited the study site seven times during the study: once during the 2-week screening period (week −2), five times during the active treatment period (weeks 0, 2, 4, 8 and 12), and once more at the end of the 4-week follow-up period (week 16)."
507,PMC5418559,S43,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,the study was conducted in accordance with the declaration of helsinki and all patients provided written informed consent.
508,PMC5418559,S45,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,men and women aged 18–75 years who met the rome iii criteria for ibs-c (20) were eligible for study enrollment.
509,PMC5418559,S46,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"in addition, patients had to have had a colonoscopy within the past 10 years if more than 50 years of age or in the presence of unexplained warning symptoms (e.g., lower gastrointestinal bleeding, iron-deficiency anemia, clinically significant weight loss, and systemic signs of infection or colitis), and agree to use appropriate methods of contraception, or be surgically sterile or post-menopausal."
510,PMC5418559,S47,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"the main exclusion criteria were: functional diarrhea, ibs with diarrhea, mixed ibs or un-subtyped ibs, as defined by rome iii criteria; any clinically symptomatic biochemical or structural abnormality or active disease of the gastrointestinal tract within 6 months before screening; use of medications that are known to affect stool consistency (except as described below); hepatic dysfunction (defined as alanine aminotransaminase/serum glutamic-pyruvic transaminase or aspartate aminotransaminase/serum glutamic-oxaloacetic transaminase >2.5 × the upper limit of normal) or renal impairment (serum creatinine >2 mg/dl); any surgery on the stomach, small intestine or colon (excluding appendectomy); a major psychiatric disorder requiring hospitalization in the last 3 years, or a history of attempted suicide or uncontrolled bipolar disorder; or clinical evidence of any significant disease that may interfere with the patient successfully completing the trial."
511,PMC5418559,S48,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,pregnant or lactating women were also excluded.
512,PMC5418559,S49,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"after the 2-week screening period, in order for patients to be randomly assigned to study treatment, they needed to complete symptom assessments via a touch-tone telephone diary for at least 11 out of 14 days to ensure that they were diary compliant and meet the following study entry criteria: average weekly stool frequency of five or fewer spontaneous bowel movements (sbms), defined as all non-aided bowel movements, and two or fewer complete spontaneous bowel movements (csbms), defined as a bowel movement accompanied by a sensation of complete evacuation; an average weekly stool consistency score of 3 or less using the bristol stool form scale (bsfs) (21); an average weekly abdominal pain score of at least 3 on a 0–10-point scale; and no liquid stools for any sbm or mushy stools for more than one sbm according to the bsfs."
513,PMC5418559,S50,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Patients,rescue medication (bisacodyl 5 mg tablet or 10 mg suppository) was allowed for a maximum of 2 days during the screening period but not during the 48 h before randomization.
514,PMC5418559,S51,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Patients,"during the study, rescue medication was allowed to relieve severe constipation (defined as at least 72 h without a bowel movement or when symptoms became intolerable)."
515,PMC5418559,S52,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Patients,bowel movements were not considered to be sbms and csbms if they were reported <24 h after the use of rescue medication.
516,PMC5418559,S53,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Patients,"patients who were on a stable, continuous regimen of fiber, bulk laxatives, stool softeners, and/or probiotics during the 30 days before the screening visit were included in the study and, provided that they maintained the same treatment and dose throughout the trial, were included in the analysis."
517,PMC5418559,S55,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy variables,the csbm responder rate was the primary efficacy variable in this study.
518,PMC5418559,S56,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy variables,"secondary efficacy variables included a composite of the csbm responder rate and the abdominal pain responder rate, and the responder rates for individual abdominal symptoms including abdominal discomfort, abdominal bloating, abdominal fullness, and abdominal cramping."
519,PMC5418559,S57,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy variables,"additional secondary efficacy variables were weekly averages of stool frequency, stool consistency, straining, abdominal pain, constipation severity, and ibs severity."
520,PMC5418559,S58,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy variables,"degree of relief from ibs symptoms, and treatment satisfaction at 12 weeks were additional secondary efficacy variables."
521,PMC5418559,S60,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy variables,data for all efficacy variables were recorded by patients using the touch-tone telephone diary.
522,PMC5418559,S61,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy variables,"variables recorded daily included stool frequency (csbms and sbms), stool consistency (bsfs), abdominal symptom scores (pain, bloating, cramping, discomfort, and fullness; each on a 0–10-point scale, 0=absent, 10=very severe), and a straining score (1–5-point scale, 1=not at all, and 5=an extreme amount)."
523,PMC5418559,S62,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy variables,"variables scored weekly by patients included constipation severity, ibs severity (each on a 1–5-point scale, 1=none, 5=very severe), degree of relief from ibs symptoms (1–7-point scale, 1=completely relieved, 7=as bad as i can imagine), and treatment satisfaction (1–5-point scale, 1=not at all satisfied, 5=very satisfied)."
524,PMC5418559,S64,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy variables,the csbm responder rate was defined as the proportion of patients with an increase of at least one csbm/week compared with baseline for at least 6 of the 12 treatment weeks.
525,PMC5418559,S65,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy variables,"the baseline value was defined as the average of the number of csbms per week for the 2-week screening period (i.e., weeks −1 and −2)."
526,PMC5418559,S66,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy variables,"responder rates for individual abdominal symptoms (abdominal pain, bloating, cramping, discomfort, and fullness) were defined as the proportion of patients with a decrease of at least 30% from baseline in the average weekly severity score for at least 6 out of 12 treatment weeks."
527,PMC5418559,S67,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy variables,"a composite responder rate (22) was calculated as the proportion of patients with an increase of at least one csbm/week from baseline (primary efficacy variable) and a decrease of at least 30% from baseline in average weekly abdominal pain severity score during the same week, for at least 6 out of 12 treatment weeks."
528,PMC5418559,S69,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Safety variables,adverse events (aes) were monitored throughout the trial.
529,PMC5418559,S70,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Safety variables,they were reported by the patient spontaneously and/or in response to an open question from study personnel at each site visit.
530,PMC5418559,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Safety variables,"safety assessments included: vital signs at each visit (systolic and diastolic blood pressure, heart rate, respiratory rate, body temperature, and weight); clinical laboratory tests (serum electrolytes, hematology, and urinalysis) at weeks −2, 4, and 12; physical examinations at weeks −2, 12, and 16; and 12-lead electrocardiogram monitoring at weeks −2 and 12."
531,PMC5418559,S72,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Safety variables,"blood samples for pharmacokinetic assessments of tenapanor were collected at site visits at weeks 8 and 12, 1–4 h after morning dosing, from subsets of ~30 randomly selected patients per group."
532,PMC5418559,S74,"['8a', '10']","[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0]",Statistical methods,a computer-generated randomization scheme was made available to all clinical centers participating in the study via an interactive web response system.
533,PMC5418559,S75,['9'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1]",Statistical methods,the packaging and labeling of the study drug kits were based on a separate drug packaging randomization schedule.
534,PMC5418559,S76,"['8b', '8a', '10']","[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0]",Statistical methods,the interactive web response system determined which drug package the center should administer to the patient based on a randomization schedule where each treatment was allocated once using a block size of four within each study site.
535,PMC5418559,S77,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"this ensured whole or partial block sizes were allocated, facilitating even distribution of patients amongst each dose group."
536,PMC5418559,S78,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical methods,data collected from the touch-tone telephone diary system throughout the study were automatically entered into a database; any abnormal values were automatically flagged so the relevant site could follow-up with the patient for clarification.
537,PMC5418559,S79,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,compliance to study treatment was determined based on the amount of unused study drug returned to study sites.
538,PMC5418559,S80,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,the intention-to-treat analysis set included all patients who received at least one dose of study drug/placebo and for whom at least one valid week of efficacy assessment data had been collected.
539,PMC5418559,S81,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical methods,a valid week required at least four non-missing days.
540,PMC5418559,S82,"['6a', '12a']","[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical methods,"scores for stool frequency were standardized to 7 days, with missing days during the week being imputed with the average for the non-missing days."
541,PMC5418559,S83,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical methods,the average weekly scores for other efficacy variables were calculated from the observed number of responses without any standardization.
542,PMC5418559,S84,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,the safety analysis set included all patients who received at least one dose of study drug or placebo.
543,PMC5418559,S85,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical methods,a sample size of 90 patients in each treatment group was expected to provide 80% power to detect a difference of 20% in the csbm responder rate between the placebo group and at least one of the tenapanor treatment groups.
544,PMC5418559,S86,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical methods,an assumed responder rate of 20% in patients treated with placebo was based on historical data from a similar trial in patients with ibs-c (23); an assumed responder rate of 40% in patients treated with tenapanor was considered to be clinically meaningful in this patient population.
545,PMC5418559,S87,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"the primary efficacy variable, the csbm responder rate, was analyzed using a cochran–mantel–haenszel (cmh) test with pooled investigator sites as a stratification variable."
546,PMC5418559,S88,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,a closed testing procedure was used to control the experiment-wise type i error rate at the 5% significance level.
547,PMC5418559,S89,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"a cmh screening test was conducted first (for the primary efficacy variable only) to look for an association between treatment and responder rate across the placebo, tenapanor 20 mg b.i.d., and tenapanor 50 mg b.i.d. treatment groups."
548,PMC5418559,S90,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"if the result of this test was found to be statistically significant at the 5% level, each of the tenapanor 20 mg b.i.d. and 50 mg b.i.d. treatment groups were compared with the placebo group using a 5% significance level."
549,PMC5418559,S91,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"if either or both of these comparisons were found to have a significant result, either or both of these treatment groups were considered to be individually or simultaneously significantly different from the placebo group."
550,PMC5418559,S92,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"if both the tenapanor 20 mg b.i.d. and tenapanor 50 mg b.i.d. treatment groups were significantly different from the placebo group, the tenapanor 5 mg b.i.d. treatment group was compared with the placebo group using a 5% significance level."
551,PMC5418559,S93,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"cmh pairwise comparison tests of all tenapanor doses vs. placebo were used to evaluate the abdominal pain responder rate, the composite responder rate, and the responder rates for other abdominal symptoms (abdominal bloating, cramping, discomfort, and fullness)."
552,PMC5418559,S94,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"continuous efficacy variables were assessed using an analysis of covariance model with pooled investigator sites and treatment group as terms and with baseline as the covariate, or an analysis of variance model with pooled investigator sites and treatment as terms."
553,PMC5529963,S100,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,the greenhouse-geisser correction for the f test was used to adjust the degrees of freedom for deviation from sphericity.
554,PMC5529963,S101,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,analysis was performed using graphpad prism analysis software.
555,PMC5529963,S102,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,a two-sided p value of <0.05 was considered to indicate statistical significance.
556,PMC5529963,S103,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,an additional multilevel logistic regression analysis was conducted in r to confirm our results (see online supplementary appendix 2).
557,PMC5529963,S104,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,we fit multilevel logistic regression models for measure of hdl function using the lme4 package (http://cran.r-project.org/web/packages/lme4/index.html) in the r statistical language (http://www.r-project.org/).
558,PMC5529963,S105,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,all coefficients were taken as random effects.
559,PMC5529963,S106,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,10.1136/heartjnl-2015-308953.supp2
560,PMC5529963,S107,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,supplementary appendix 2
561,PMC5529963,S36,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,"we studied 18 patients with early erosive ra who were required to have (i) a diagnosis of ra according to the american college of rheumatology 1987 criteria, (ii) symptoms for 6 months—3 years, (iii) a minimum of two swollen metacarpophalangeal (mcp) joints despite treatment with mtx and (iv) seropositivity for igm rheumatoid factor."
562,PMC5529963,S37,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,"in addition, eligible patients were required to have either (i) erosion of ≥1 mcp joint as demonstrated on plain radiography or as a cortical break with irregular margins (or contour) on greyscale ultrasound in both the longitudinal and transverse scanning planes or (ii) erosions of ≥2 mcp joints (cortical breaks with irregular margins/contour on greyscale ultrasound in either the transverse or the longitudinal plane associated with a strong vascular signal in power doppler mode at the site of the cortical break).7"
563,PMC5529963,S38,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,"all patients received oral mtx for greater than or equal to at least 8 weeks, at a minimum stable dosage of 12.5 mg/week but not exceeding 17.5 mg/week."
564,PMC5529963,S39,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,patients being treated with oral corticosteroids must have been receiving a stable dosage (10 mg prednisolone per day) for 4 weeks.
565,PMC5529963,S41,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,vascular properties of hdl from 18 patients with ra were compared with 18 healthy control subjects.
566,PMC5529963,S42,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,"healthy controls had no cv risk factors by history, clinical examination and laboratory tests, and were matched to patients with ra for age and gender."
567,PMC5529963,S44,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,"all physicians, patients, nurses and other non-clinical members of the study team were blinded for the first year of the study."
568,PMC5529963,S45,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,eighteen patients with ra were randomised into one of two treatment groups by a pharmacist who did not participate in the screening visit.
569,PMC5529963,S46,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,"eleven patients received infusions of infliximab at 5 mg/kg and seven received placebo (normal saline) infusions at weeks 0, 2 and 6, and then every 8 weeks through week 46."
570,PMC5529963,S47,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,"at the end of the first year, all patients were maintained a single-blinded study for a further year."
571,PMC5529963,S48,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,"patients in the methotrexate+infliximab (m+i ) group received infliximab infusions at weeks 54, 56, 62 and thereafter every 8 weeks."
572,PMC5529963,S49,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,those in the m+i group received a placebo infusion at week 56 in order to maintain blinding and received infliximab infusions every 8 weeks until the end of the study (110 weeks) (see online supplementary appendix figure 1).
573,PMC5529963,S50,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,"as a result, all patients received a minimum of 1 year of infliximab in the two phases of the study."
574,PMC5529963,S51,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,10.1136/heartjnl-2015-308953.supp1
575,PMC5529963,S52,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,supplementary appendix 1
576,PMC5529963,S53,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,baseline dosages of mtx or corticosteroid were maintained during the first 18 weeks of the study.
577,PMC5529963,S54,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,"after week 18, if any patient failed to achieve a 50% reduction from baseline in the number of swollen hand and wrist joints, the weekly dose of mtx was increased by 2.5 mg once every 4 weeks until a 50% reduction from baseline in the number of swollen hand and wrist joints was achieved, until the dosage of oral mtx reached 25 mg/week or until the dose escalation was limited by toxicity."
578,PMC5529963,S55,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,"thereafter, irrespective of their response status, patients continued to receive the maximum tolerated mtx dosage until the end of the study."
579,PMC5529963,S56,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,"the study was approved by riverside research ethics committee, and all patients provided informed consent."
580,PMC5529963,S57,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,"clinical monitoring of the study was performed independently (centocor, malvern, pennsylvania, usa)."
581,PMC5529963,S60,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,anthropometric measurements were made and body mass index (bmi (kg/m2)) was calculated from weight and height.
582,PMC5529963,S61,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"blood pressure was measured in triplicate (hem-705cp, omron), and the average of the readings was calculated."
583,PMC5529963,S62,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"blood was drawn and processed after an overnight fast, and serum and plasma samples were stored at −70°c for subsequent analysis."
584,PMC5529963,S63,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"full blood count, lipid and glucose level measurements were made with standard biochemistry assays and c reactive protein (crp) was measured with an immunoturbidimetric, high-sensitivity assay (tina-quant assay performed on a cobas integra analyzer, roche diagnostics)."
585,PMC5529963,S65,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"measurements of hdl function were carried out at baseline, 54 weeks and 110 weeks in patients with ra."
586,PMC5529963,S66,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Laboratory assays,baseline measurements were compared with those from healthy controls.
587,PMC5529963,S68,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,hdl was isolated by sequential ultracentrifugation (d=1.063–1.21 g/ml) using solid potassium bromide for density adjustment.8
588,PMC5529963,S69,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,all functional assays of hdl were carried out within two weeks of isolation by a blinded investigator in duplicate.
589,PMC5529963,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"the effect of hdl (50 μg/ml: 60 min, 37°c) on endothelial nitric oxide (no) bioavailability (bovine aortic endothelial cells (baecs): passage 4–7; lonza bioscience) was measured using a fluorescent indicator."
590,PMC5529963,S72,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"baecs were incubated with 4,5-diaminofluorescein diacetate (daf-2; 1um; cayman chemical), and triazolofluorescein fluorescence was measured using an excitation wavelength of 485 nm.9"
591,PMC5529963,S74,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"the effect of hdl on endothelial cell superoxide production (so) was measured in unstimulated and tumour necrosis factor-α (tnf-α)-stimulated (5 ng/ml, r&d systems) human aortic endothelial cells (haecs) by erythrocyte sedimentation rate (esr) spectroscopy."
592,PMC5529963,S75,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"haecs were incubated with hdl from patients and controls (50 μg/ml, 60 min, 37°c), with or without tnf-α and resuspended in krebs-hepes buffer (ph 7.4; noxygen) containing diethyldithiocarbamic acid sodium salt (5 μm, noxygen) and deferoxamine methanesulfonate salt (25 μm, noxygen)."
593,PMC5529963,S76,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"esr spectra were recorded after addition of the spin probe 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine (cmh; noxygen; final concentration 200 μm) using a bruker e-scan spectrometer (bruker biospin)."
594,PMC5529963,S77,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,the esr instrumental settings were centre field (b0) 3495 g; field sweep width 10 g; microwave frequency 9.75 ghz; microwave power 19.91 mw; magnetic field modulation frequency 86.00 khz; modulation amplitude 2.60 g; conversion time 10.24 ms; and number of x-scans 1020.9
595,PMC5529963,S79,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,hdl for measurements of efflux capacity was extracted from serum by apob depletion.
596,PMC5529963,S80,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"whole serum was incubated for 20 min with a 20% polyethylene glycol (peg) solution (20% peg 8000 (sigma p2139) in 200 mm glycine (sigma g8898, ph=10))."
597,PMC5529963,S81,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"samples were centrifuged at 1900 g, and the supernatant was collected and stored at 4°c."
598,PMC5529963,S82,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,j774 cells were radiolabeled for 24 hours in a medium containing 2 μci of [3h]-cholesterol per microlitre.
599,PMC5529963,S83,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,addition of 0.3 mm 8-(4-chlorophenylthio)-cyclic amp for 6 hours upregulated expression of abca1.
600,PMC5529963,S84,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,an efflux medium containing 2.8% apolipoprotein b-depleted serum from each individual was added for 4 hours.
601,PMC5529963,S85,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"to prevent cholesterol esterification during labelling, equilibration and flux, 2 μg/ml of cp113,818, a acyl-coenzyme a:cholesterol acyltransferase inhibitor was added to all mediums."
602,PMC5529963,S86,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,efflux capacity was quantified using liquid scintillation to measure radioactive cholesterol effluxed from the cells (medium+intracellular lipids).
603,PMC5529963,S87,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,all assays were performed in duplicate and the final average value normalised against a baseline control for statistical analyses between time points.10
604,PMC5529963,S89,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"serum paraoxonase activities were measured by ultraviolet spectrophotometry in a 96-well plate format using paraoxon (sigma-aldrich, st louis, missouri, usa)."
605,PMC5529963,S90,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"briefly, 50 μg/ml hdl was diluted in a reaction mixture containing 10 mm tris hydrochloride (ph 8.0), 1 m sodium chloride and 2 mm calcium chloride."
606,PMC5529963,S91,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"at 24°c, 1.5 mm paraoxon was added to initiate the reaction, and the increase in absorbance at 405 nm was recorded over 30 min. an extinction coefficient (at 405 nm) of 17 000 m−1 • cm−1 was used to calculate units of paraoxonase-1 (pon-1).11"
607,PMC5529963,S93,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistics,"hdl studies were powered for a 1:1 randomised controlled trial on the basis of no bioavailability using paired assessments in 35 healthy controls (mean=0.98, sd =0.13, and intraclass correlation 0.91).12"
608,PMC5529963,S94,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistics,"from this power calculation, a total of seven patients per group was required (power=80% and α=0.05) to detect a 5% difference in the primary outcome (no bioavailability)."
609,PMC5529963,S95,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,normal distribution was assessed using the shapiro-wilk test.
610,PMC5529963,S96,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,all measures are reported as mean (sd) or median (iqr) for those not normally distributed.
611,PMC5529963,S97,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,baseline comparisons were performed using an independent t-test or mann-whitney u test if data was non-normally distributed.
612,PMC5529963,S98,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,"post hoc multivariate analysis of variance (anova) modelling was performed to evaluate the effects of treatment with infliximab (vs placebo) and duration of treatment on hdl function, cv and clinical markers at 54 weeks."
613,PMC5529963,S99,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,"a repeated-measures anova, with time point comparisons using bonferroni-corrected t-tests, was performed to determine differences in hdl function, cv and clinical markers in patients who received 2 years infliximab treatment."